ars.els-cdn.com · Web viewTable S1: Clinical trials currently being undertaken globally for the treatment of novel coronavirus (COVID-19) pneumonia. REGISTRATION NUMBER & TITLE

Table S1: Clinical trials currently being undertaken globally for the treatment of novel coronavirus (COVID-19) pneumonia.

REGISTRATION NUMBER & TITLE

COUNTRY & SITE(S) TYPE OF STUDY GENERAL CATEGORY OF INTERVENTION

MAIN ITERVENTION(S)/ARMS

DOSE(S) PRIMARY OUTCOME(S) AGE OF PARTICIPANTS

1. oXiris Memzne in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19) ChiCTR2000030477

CHINA,Peking Union Medical College Hospital

InterventionalSingle-centreSingle-arm Open-label

Adjuvant Device(oΧiris® membrane: endotoxin and cytokine reducing membrane)

oΧiris® membrane group N/A 28-day mortalityMeasure time point of outcome：28 Days after treatment

>18y.o.

2. Cytosorb in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19) ChiCTR2000030475

CHINA,Tongji Hospital

InterventionalSingle-centre Single-arm Open-label

Adjuvant Device(CytoSorb device: cytokine reducing device)

CytoSorb device group N/A 28-day mortalityMeasure time point of outcome：28 Days after treatment

>18y.o.

3. A randomized controlled trial for the Efficacy of Ultra Short Wave Electrotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19) ChiCTR2000029972


InterventionalSingle-centre Open-labelControlled

Adjuvant Device(Ultra Short Wave Electrotherapy)

Lung Ultra Short Wave ElectrotherapyvsStandard treatment

N/A Rate of Coronary virus nucleic acid negative at 7 days, 14 days, 21 days, and 28 days after Ultra Short-Wave ElectrotherapyMeasure time point of outcome Day 7, 14, 24, 28Symptom recovery at 7 days, 14 days, 21 days, and 28 days after Ultra Short-Wave ElectrotherapyMeasure time point of outcome Day 7, 14, 24, 28

18-65y.o.

4. Study for continuous renal replacement therapy with adsorption filter in the treatment of the novel coronavirus pneumonia (COVID-19) ChiCTR2000030265

CHINA,The First Affiliated Hospital of Harbin Medical University

Interventional RandomisedOpen-labelControlled

Adjuvant device (oΧiris® continuous renal replacement therapy -CRRT)

High inflammation oXiris CRRT treatment groupvsHigh inflammation standard treatment groupvsLow inflammation standard treatment group

N/A Inflammation factor7-day mortality

18-85y.o.

5. A medical records based study for the safety of artificial liver cluster nursing in critically ill patients with novel coronavirus pneumonia (COVID-19) (http://www.chictr.org.cn/showprojen.aspx?proj=50583 ) ChiCTR2000030559

CHINA,The First Affiliated Hospital of Zhejiang University, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Disease

Retrospective Observational Study

Adjuvant Device (Artificial Liver System)

Patients with blood purification therapy

N/A Unplanned shutdowns. ≥18y.o.

6. Extracorporeal blood purification therapy using Li's Artificial Liver System for patients with severe novel coronavirus pneumonia (COVID19) patient (http://www.chictr.org.cn/showprojen.aspx?proj=49632 ) ChiCTR2000030503

CHINA,The First Affiliated Hospital of Zhejiang University,Hubei General Hospital

InterventionalNon-randomisedParallel-controlled

Adjuvant Device (Artificial Liver System)

Hemadsorption + conventional treatmentvsStandard treatment

N/A Mortality ≥18y.o.

7. Continuous renal replacement therapy (CRRT) alleviating inflammatory response in severe patients with novel coronavirus

CHINA,Lei Shen Shan Hospital, Wuhan city

InterventionalSingle-arm

Adjuvant Device (Continuous renal replacement therapy)

CRRT N/A C-reactive protein, Interleukin 6, Interleukin 8, Tumour necrosis factor alpha.

≥16y.o.

http://www.chictr.org.cn/showprojen.aspx?proj=49632
















pneumonia (COVID-19) associated with renal injury: A Prospective study (http://www.chictr.org.cn/showprojen.aspx?proj=50956 ) ChiCTR2000030761

8. Research for the mechanism of improvement of novel coronavirus pneumonia (COVID-19) patients' pulmonary exudation by continuous renal replacement therapy (http://www.chictr.org.cn/showprojen.aspx?proj=50658 ) ChiCTR2000030540

CHINA,Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

InterventionalRandomisedParallel-controlled

Adjuvant Device (Continuous renal replacement therapy)

CRRTvsStandard treatment

N/A Chest imaging, Oxygenation index, Extravascular pulmonary water, pulmonary vascular permeability index, PVPI, Inflammatory factors, Tissue kallikrein.

18-90 y.o.

9. Clinical study for the effects of ACEIs/ARBs on the infection of novel coronavirus pneumonia (CoVID-19) ChiCTR2000030453

CHINA,The First Affiliated Hospital of Wenzhou Medical University

Retrospective Observational study

Angiotensin-converting enzyme inhibitor / Angiotensin II receptor blocker

Patients who received Angiotensin-converting enzyme inhibitors or Angiotensin II receptor blockers

N/A A cycle threshold value (Ct-value).

N/A

10. Losartan for Patients With COVID-19 Not Requiring Hospitalization(https://www.clinicaltrials.gov/ct2/show/NCT04311177 ) NCT04311177

UNITED STATES,University of Minnesota, Hennepin County Medical Center, M Health Fairview University of Minnesota Medical Center.

InterventionalRandomisedPlacebo-controlledDouble-blindMulticentre

Angiotensin-converting enzyme inhibitor / Angiotensin II receptor blocker(Losartan)

Losartanvs Placebo

Losartan: 25 mg OD (PO)

Hospital Admission [Time Frame: 15 days]Outcome reported as the number of participants per arm admitted to inpatient hospital care due to COVID-19-related disease within 15 days of randomization.Currently, there is a pre-planned pooled analysis with a national trial network under development

≥18y.o.

11. Losartan for Patients With COVID-19 Requiring Hospitalization (https://clinicaltrials.gov/ct2/show/NCT04312009) NCT04312009

UNITED STATES,University of Minnesota, Hennepin County Medical Center, M Health Fairview University of Minnesota Medical Center.

InterventionalRandomisedPlacebo-controlledDouble-blindMulticentre

Angiotensin-converting enzyme inhibitor / Angiotensin II receptor blocker(Losartan)

Losartan vsPlacebo

Losartan: 25mg OD (PO)

Difference in Estimated (PEEP adjusted) P/F Ratio at 7 days [Time Frame: 7 days]Outcome calculated from the partial pressure of oxygen or peripheral saturation of oxygen by pulse oximetry divided by the fraction of inspired oxygen (PaO2 or SaO2:FiO2 ratio). PaO2 is preferentially used if available. A correction is applied for endotracheal intubation and/or positive end-expiratory pressure. Patients discharged prior to day 7 will have a home pulse oximeter send home for measurement of the day 7 value, and will be adjusted for home O2 use, if applicable. Patients who died will be applied a penalty with a P/F ratio of 0.

≥18y.o.

12. A randomized, open-label controlled trial for the efficacy and safety of Pirfenidone in patients


Interventional RandomisedOpen-label

Anti-fibrotic Agent(Pirfenidone)

Standard treatment + Pirfenidonevs

Pirfenidone: 400mg TID (PO) for ≥4weeks

Chest Computed Tomography [Time Frame: 4 weeks]Lesion area of chest CT image at

≥18y.o.



https://clinicaltrials.gov/ct2/show/NCT04312009


https://www.clinicaltrials.gov/ct2/show/NCT04311177









with severe and critical novel coronavirus pneumonia (COVID-19), (https://clinicaltrials.gov/ct2/show/NCT04282902) NCT04282902, ChiCTR2000030333

Single-centre Controlled

Standard treatment only 4 weeksFinger pulse oxygen [Time Frame: 4 weeks]Absolute change in pulse oxygen from baselineBlood gas [Time Frame: 4 weeks]Absolute change in blood gas from baselineK-BILD [Time Frame: 4 weeks]Absolute change in total score of King's brief questionnaire for interstitial Absolute change in total score of King's brief questionnaire for interstitial pulmonary disease (k-bild) from baseline at week 4

13. Efficacy and Safety of Pirfenidone in the Treatment of Severe Post-Novel Coronavirus Pneumonia (COVID-19)) Fibrosis:a prospective exploratory experimental medical study (http://www.chictr.org.cn/showprojen.aspx?proj=51118 ) ChiCTR2000030892

CHINAThe First Affiliated Hospital of Guangzhou Medical University

Interventional RandomisedOpen -labelSingle-centreControlled

Anti-fibrotic Agent (Pirfenidone)

Standard Treatment + Pirfenidone vs Standard treatment

N/A High resolution Computed Tomography pulmonary fibrosis scoreMeasure time point of outcome: Baseline, 7th day, 14th day, discharge period, 12th week

18-80y.o.

14. Prospective exploratory clinical research on the efficacy and safety of pirfenidone capsules in the treatment of severe novel coronavirus pneumonia (COVID-19) (http://www.chictr.org.cn/showprojen.aspx?proj=51416 ) ChiCTR2000031138

CHINA, The third xiangya hospital of Central South University The Fourth People's Hospital of Yueyang

InterventionalRandomisedMulticentreControlled

Anti-fibrotic Agent (Pirfenidone)

Support treatment + PirfenidonevsSupport treatment

N/A High resolution Computed Tomography pulmonary fibrosis scoreMeasure time point of outcome: Base line, week 1, 2, 4 after enrolment

18-80y.o.

15. A prospective, randomized, open label, controlled trial for chloroquine and hydroxychloroquine in patients with severe novel coronavirus pneumonia (COVID-19) ChiCTR2000029992

CHINA,Zhongshan Hospital Affiliated to Xiamen University


Anti-malaria Drug(Chloroquine and Hydroxychloroquine)

Chloroquine phosphatevsHydroxychloroquine sulphatevsStandard treatment

Chloroquine phosphate: 1g BID for 2 days and then 0.5g BID (PO)Hydroxychloroquine sulphate: 0.2g BID for 14 days (PO)

Clinical recovery timeMeasure time point of outcome: The twenty-eighth daysMeasure method: There are at least 2 improvements in clinical status grading (from discharge 1 to death 6) of 6 indicators in clinical evaluationChanges in viral load of upper and lower respiratory tract samples compared with the baselineMeasure time point of outcome: The twenty-eighth daysMeasure method：2019-nCoV nucleic acid Polymerase chain reaction fluorescence probe method

18-75y.o.

16. Clinical Study of Chloroquine CHINA, Interventional Anti-malaria Drug Chloroquine phosphate N/A Time to Clinical Recovery. 18-70y.o.













Phosphate in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19) ChiCTR2000029988

Zhongnan Hospital of Wuhan University

RandomisedOpen-labelControlled

(Chloroquine) vsNo intervention

17. Single arm study for exploration of chloroquine phosphate aerosol inhalation in the treatment of novel coronavirus pneumonia (COVID-19) ChiCTR2000029975

CHINA,The First Hospital of Jilin University

Interventional Single-armOpen-label

Anti-malaria Drug(Chloroquine)

Chloroquine phosphate aerosol inhalation

150mg Chloroquine phosphate dissolved in 5ml of normal saline, BID inhaled by atomization for one week.

Viral negative-transforming time, 30-day cause-specific mortality.

≥18y.o.

18. A Single-blind, Randomized, Controlled Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19) ChiCTR2000029939

CHINA,HwaMei Hospital, University of Chinese Academy of Sciences

Interventional Single-blindRandomisedControlled


Standard treatment + Chloroquine phosphatevsStandard treatment

N/A Length of hospital stay. ≥18y.o.

19. A Single-arm Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19) ChiCTR2000029935




Standard treatment + Chloroquine phosphate

N/A Length of hospital stay. ≥18y.o.

20. Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Mild and Commen Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-label, Parallel, Controlled Trial ChiCTR2000029899

CHINA,Peking University Third Hospital, Tongji Hospital, The First Affiliated Hospital of Nanchang University, Beijing Haidian Hospital (Haidian Section of Peking University Third Hospital)

Interventional RandomisedOpen-labelParallel-controlled


Chloroquine phosphatevsHydroxychloroquine sulphate

Hydroxychloroquine sulphate: Day1: 1st dose: 0.6g, 2nd dose after 6h:0.6g Day2-5: 0.2g BID (PO)Chloroquine phosphate: Day1-3: 500mg BID Day4-5: 250m g BID (PO)

Time to Clinical Recovery (TTCR)Measure time point of outcome: within 28 days after randomization

≥18y.o.

21. Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Severe Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-Label, Parallel, Controlled Trial ChiCTR2000029898

CHINA,Peking University Third Hospital, Tongji Hospital, The First Affiliated Hospital of Nanchang University, Beijing Haidian Hospital (Haidian Section of Peking University Third Hospital)

Interventional RandomisedOpen-labelParallel-controlled


Chloroquine phosphatevsHydroxychloroquine sulphate

Hydroxychloroquine sulphate: Day1: 1st dose: 0.6g, 2nd dose after 6h:0.6g Day2-5: 0.2g BID (PO)Chloroquine phosphate: Day1-3: 500mg BID Day4-5: 250m g BID (PO)

Time to Clinical Improvement (TTCI)Measure time point of outcome: within 28 days after randomization

18-75y.o.

22. Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19) ChiCTR2000029559

CHINA,Renmin Hospital of Wuhan University

Interventional RandomisedDouble-blindPlacebo-controlled

Anti-malaria Drug(Hydroxychloroquine)

Hydroxychloroquine sulphate low dosevsHydroxychloroquine sulphate high dosevsPlacebo

Hydroxychloroquine sulphate low dose: 0.1g BID (PO)Hydroxychloroquine sulphate high dose0.2g BID (PO)

The time when the nucleic acid of the novel coronavirus turns negative, T cell recovery time

30-65y.o.

23. Treatment of Coronavirus SARS- FRANCE, Interventional Anti-malaria Drug Hydroxychloroquine Hydroxychloroqui Results of SARS-COV-2 virus ≥12y.o





















Cov2 Respiratory Infections with Hydroxychloroquine (https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000890-25/FR/) EudraCT Number: 2020-000890-25

FondationMéditerranée Infection (FMI)

Single-centreSingle-arm

(Hydroxychloroquine) ne: 200 mg detectionTime point(s) of evaluation of this end point: Day 1, Day 4, Day 7 and Day 14

24. Randomized controlled trial of hydroxychloroquine versus placebo for the treatment of adult patients with acute coronavirus disease 2019 – COVID-19 (https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001224-33/DE/) EudraCT number: 2020-001224-33

GERMANY,University hospital of Tübingen

Interventional RandomisedPlacebo-controlled


HydroxychloroquinevsPlacebo

N/A Viral clearance defined as time to sustained SARS-CoV-2-specific RNA copy number ≤100, measured by real time reverse-transcription polymerase chain reaction in throat swabsTimepoint(s) of evaluation of this end point : One interim analysis for evaluating the primary efficacy endpoint is planned for this study. The interim analysis will be done when 40% of events have accrued. In case the interim analysis shows a HR > 1.93 (nominal p < 0.0018), efficacy is shown and the trial may be stopped. Final analysis upon completion of the trial and final database lock.

≥18y.o.

25. Randomized controlled trial for the efficacy of dihydroartemisinine piperaquine in the treatment of mild/common novel coronavirus pneumonia (COVID-19) ChiCTR2000030082

CHINA,Cancer Center, Xiehe Hospital

Interventional RandomisedControlled

Anti-malaria Drug(Dihydroartemisinine piperaquine)InterferonOther antiviral(Umifenovir)

Interferon alpha+ Umifenovir + Dihydroartemisinin piperaquinevsInterferon alpha+ Umifenovir

Interferon alpha: 5 million U BID (INH) for 7 daysUmifenovir: 0.2 TID (PO) for 7 daysDihydroartemisinin piperaquine: 80mg /640mg BID (PO) for 7 days

The time when the nucleic acid of the novel coronavirus turns negative.

18-80y.o.

26. A prospective, open label, randomized, control trial for chloroquine or hydroxychloroquine in patients with mild and common novel coronavirus pulmonary (COVIP-19) ChiCTR2000030054

CHINA,Zhongshan Hospital Affiliated to Xiamen University



Hydroxychloroquine sulphatevsChloroquine phosphatevsStandard treatment

Hydroxychloroquine sulphate: 0.2g BID for 14 days Chloroquine phosphate: 1g for 2 days, then 0.5g for 12 days

Clinical recovery timeMeasure time point of outcome: The twenty-eighth days

18-75y.o.

27. Hydroxychloroquine treating novel coronavirus pneumonia (COVID-19): a multicenter, randomized controlled trial ChiCTR2000029868

CHINA,Ruijin Hospital, Suizhou Central Hospital ,Xiaogan Central Hospital, Wuhan 7th Hospital, Ezhou Central Hospital, Jingzhou First People's Hospital, Xiangyang 1st People's Hospital

Interventional RandomisedMulticentreControlled


Hydroxychloroquine sulphatevsStandard treatment

Hydroxychloroquine sulphate: 400mg TID on Day1-3, then 400mg BID on Day 4-14 (PO)

Viral nucleic acid test. ≥18y.o.

28. Efficacy of Chloroquine and CHINA, Interventional Anti-malaria Drug Lopinavir/ritonavir N/A Length of stay ≥18y.o.











https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001224-33/DE/



https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000890-25/FR/



Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study ChiCTR2000029741

The Fifth Affiliated Hospital Sun Yat-Sen University

RandomisedOpen-labelControlledMulticentre

(Chloroquine)Protease Inhibitor(Lopinavir/ritonavir)

vsChloroquine phosphate

Length of severeOxygenation index during treatmentMeasure time point of outcome: Day 1, 3, 5, 7, 10, 14, 21, 28All-cause mortality in 28 daysPeripheral blood cell count (including white blood cells, lymphocytes, neutrophils, etc.)Measure time point of outcome: Day 1, 3, 5, 7, 10, 14, 21, 28ProcalcitoninMeasure time point of outcome: Day 1, 3, 5, 7, 10, 14, 21, 28C-reactive proteinMeasure time point of outcome: Day 1, 3, 5, 7, 10, 14, 21, 28 Inflammatory factors (including interleukin 6, interleukin 10, Tumour necrosis alpha, etc.)Measure time point of outcome: Day 1, 3, 5, 7, 10, 14, 21, 28Lymphocyte subsets and complementMeasure time point of outcome: Day 1, 3, 5, 7, 10, 14, 21, 28Coagulation indicators (prothrombin time, activated partial prothrombin time, fibrinogen, D-dimer, platelet count)Measure time point of outcome: Day 1, 3, 5, 7, 10, 14, 21, 28Virus nucleic acidMeasure time point of outcome: Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 14, 21, 28

29. Efficacy of therapeutic effects of hydroxycholoroquine in novel coronavirus pneumonia (COVID-19) patients（randomized open-label control clinical trial (http://www.chictr.org.cn/showprojen.aspx?proj=49317) ChiCTR2000029740

CHINA,The First Hospital of Peking University



Hydroxychloroquine sulphatevsStandard treatment

Hydroxychloroquine sulphate: 0.2g BID (PO)

Oxygen indexMeasure time point of outcome: baseline, 1-week, 2-week, 3-week, 4-weekMax respiratory rateMeasure time point of outcome: baseline, 1-week, 2-week, 3-week, 4-weekLung radiographyCount of lymphocyteMeasure time point of outcome: baseline, 1-week, 2-week, 3-week, 4-weekTemperatureMeasure time point of outcome: baseline, 1-week, 2-week, 3-week, 4-weekOther infectionTime when the nucleic acid of the novel coronavirus turns

16-99y.o.





negativePrognosis

30. A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in patients with novel coronavirus pneumonia (COVID-19) ChiCTR2000029609

CHINA,The Fifth Affiliated Hospital of Sun Yat-Sen University, Sun Yatsen Memorial Hospital of Sun Yatsen University

Interventional RandomisedOpen-labelControlledMulticentre

Anti-malaria Drug(Chloroquine)Protease Inhibitor(Lopinavir/ritonavir)

Mild-moderate chloroquine group (chloroquine phosphate)vsMild-moderate Lopinavir/ritonavir group (Lopinavir/ritonavir)vsMild-moderate combination group (chloroquine phosphate + Lopinavir/ritonavir)vsSevere chloroquine group (chloroquine phosphate)vsSevere Lopinavir/ritonavir group (Lopinavir/ritonavir)

Chloroquine phosphate: 0.25 gLopinavir/ritonavir:200mg/100mg

Virus nucleic acid negative-transforming time.

≥18y.o.

31. Study for the efficacy of chloroquine in patients with novel coronavirus pneumonia (COVID-19)ChiCTR2000029542

CHINA,Sun Yat-Sen Memorial Hospital



Standard treatment + Chloroquine phosphate vsStandard treatment

Chloroquine phosphate: 0.5g BID for 10 days

Viral negative-transforming time, 30-day cause-specific mortality.

18-80y.o.

32. Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV (HC-nCoV) (https://clinicaltrials.gov/ct2/show/NCT04261517) NCT04261517

CHINA,Shanghai Public Health Clinical Center



Standard treatment + Hydroxychloroquine sulphatevsStandard treatment only

Hydroxychloroquine sulphate: 400mg/day for 5 days

The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3 [Time Frame: 3 days after randomisation]The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5 [Time Frame: 5 days after randomisation]The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7 [Time Frame: 7 days after randomisation]The mortality rate of subjects at weeks 2 [ Time Frame: 14 days after randomisation]

≥18y.o.

33. Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2 (CloroCOVID19) (https://www.clinicaltrials.gov/ct2/show/NCT04323527 ) NCT04323527

BRASIL,Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz

Interventional RandomisedParallel-controlled

Anti-Malaria drug (Chloroquine)

Chloroquine diphosphate high dosevsChloroquine diphosphate low dose

Chloroquine high dose: 600 mg BID (PO)Chloroquine low dose: 450 mg BID + Placebo BID on Day 1, 450 mg OD + Placebo BID from Day 2 to Day 5, Placebo BID Day6 to Day 10 (PO)

Mortality rate reduction of 50% by day 28 [Time Frame: 28 days after randomization]Proportion of deaths at day 28 between groups compared

18-100y.o.

34. multicenter, single-blind, CHINA, Interventional Anti-malaria Drug Chloroquine phosphate N/A Clearance time of virus RNA. 18-70y.o.











randomized controlled clinical trial for chloroquine phosphate in the treatment of novel coronavirus pneumonia (http://www.chictr.org.cn/showprojen.aspx?proj=49420 ) ChiCTR2000031204

Beijing you 'an hospital, capital medical university Peking University First Hospital Beijing huimin hospital

Randomised MulticentreControlled

(Chloroquine) VsPlacebo

35. Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (https://www.clinicaltrials.gov/ct2/show/NCT04315896 ) NCT04315896

MEXICO, National Institute of Respiratory Diseases

Interventional RandomisedDouble-blinded Placebo-controlled

Anti-malaria Drug (Hydroxychloroquine)

HydroxychloroquinevsPlacebo

Hydroxychloroquine sulphate: 200mg BID (PO) for 10days

All-cause hospital mortality [Time Frame: From date of randomisation until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to120 days]Incidence of all-cause mortality

18-80y.o.

36. Norwegian Coronavirus Disease 2019 Study (https://clinicaltrials.gov/ct2/show/NCT04316377 ,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001010-38/NO/ ) NCT04316377, EudraCT Number: 2020-001010-38

NORWAY, University Hospital, Akershus

Interventional Randomised Open-labelParallel-controlled

Anti-malaria Drug (Hydroxychloroquine)

Hydroxychloroquine Sulfate + Standard treatmentvsStandard treatment

Hydroxychloroquine sulphate: 400 mg BID (PO) for 7 days

Rate of decline in SARS-CoV-2 viral load [ Time Frame: Baseline (at randomization) and at 96 hours ]Viral load assessed by real time polymerase chain reaction in nasopharyngeal samples

≥18y.o.

37. The Efficacy of Different Anti-viral Drugs in (Severe Acute Respiratory Syndrome-Corona Virus-2)( https://www.clinicaltrials.gov/ct 2/show/NCT04321616, https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000982-18/NO/ ) NCT04321616, EudraCT Number: 2020-000982-18

NORWAY, Oslo University Hospital

InterventionalRandomisedOpen-labelControlled

Anti-malaria Drug (Hydroxychloroquine)Other antiviral(Remdesivir)

HydroxychloroquinevsRemdesivirvsStandard treatment

Hydroxychloroquine: loading dose 600mg BID (PO), then 200mg TID for 10 daysRemdesivir: loading dose 200mg (IV), then 100mg OD (IV) for 9-10 days

In-hospital mortality [Time Frame: 3 weeks]All cause in-hospital mortality

≥18y.o.

38. Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention * (https://clinicaltrials.gov/ct2/show/NCT04304053 ) NCT04304053

SPAIN, CAP II Sant Fèlix, Gerència Territorial Catalunya Central, Centre de Salut Isabel Roig-Casernes de Sant Andreu

InterventionalRandomised Open-labelControlled

Anti-malaria Drug (Hydroxychloroquine) Protease Inhibitor (Darunavir/cobicistat)

Patients: Chloroquine + Darunavir/cobicistatContacts: Chloroquine prophylaxisvsPatients: Isolation + standard treatmentContacts: no prophylaxis

Patients: Darunavir/obicistat 800/150 mg OD (PO) for 7 daysHydroxychloroquine: 800mg OD (PO) on Day 1 then 400 mg OD (PO) for Days 2-7Contacts: Hydroxychloroquine: 800mg OD (PO) on Day 1, then 400mg OD (PO) for Days 2-4

Effectiveness of chemoprophylaxis assessed by incidence of secondary COVID-19 cases [Time Frame: Up to 14 days after start of treatment]Incidence of secondary cases among contacts of a case and contacts of contacts

≥18y.o.

39. Clinical study for bronchoscopic alveolar lavage in the treatment of

CHINATongji Hospital, Tongji

Prospective Observational Study

Bronchoscopic alveolar lavage

Use of fiberoptic bronchoscopy

N/A Cytology, Proteomics, Chest X-ray, Oxygenation Index.

N/A



https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000982-18/NO/














critically trachea intubation patients with new coronavirus pneumonia (COVID-19) (http://www.chictr.org.cn/showprojen.aspx?proj=51040) ChiCTR2000030857

Medical College, Huazhong University of Science and Technology

40. Safety and Effectiveness of Human embryonic stem cell-derived M cells (CAStem) for Pulmonary Fibrosis Correlated with novel coronavirus pneumonia (COVID-19) (http://www.chictr.org.cn/showprojen.aspx?proj=51404 ) ChiCTR2000031139

CHINA, Wuhan Jinyintan Hospital


Cell Therapy (Human embryonic stem cell-derived M cells)

CAStem cells Cell dose: 1x 3x10e6 cells / kg (IV), second infusion after 1 week, additional infusion possible

Pulmonary function evaluation, Changes in blood gas analysis, Evaluation of activity, Evaluation of dyspnoea, Computed Tomography changes from baseline

18-80y.o.

41. Clinical study of human NK cells and MSCs transplantation for severe novel coronavirus pneumonia (COVID-19) (http://www.chictr.org.cn/showprojen.aspx?proj=50199 ) ChiCTR2000030944

CHINA, The Second Affiliated Hospital of Nanchang UniversityJiangxi Chest Hospital


Cell therapy(Natural Killer cells, Mesenchymal Stem cells)

NK cells, MSCs + Standard TreatmentvsStandard treatment

N/A Changes of serum inflammatory factorsMeasure method: ELISAPatient death riskDrug related adverse reactions and events

4-80y.o.

42. Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19) (https://clinicaltrials.gov/ct2/show/NCT04288102) NCT04288102

CHINA,Wuhan Huoshenshan Hospital, Tianjin Haihe Hospital, Shenzhen Third People's HospitalFifth Affiliated Hospital, Sun Yat-Sen UniversityWuhan Union Hospital, China, West China Hospital

InterventionalRandomisedMulticentre Placebo-controlled

Cell Therapy(Mesenchymal Stem Cells)

Standard treatment + MSCs InfusionvsStandard treatment + Placebo

Infusion of MSCs at Day 0, Day 3, Day 6 (≥70Kg, 4.0x10e7 cells/time; <70Kg, 3.0x10e7 cells/time) (IV)

Size of lesion area and severity of pulmonary fibrosis by chest Computed Tomography [Time Frame: At Baseline , Day 6, Day 10, Day 14, Day 28 and Day 90]Evaluation of Pneumonia Improvement

18-70y.o.

43. NK Cells Treatment for Novel Coronavirus Pneumonia (https://clinicaltrials.gov/ct2/show/NCT04280224) NCT04280224

CHINA,First Affiliated Hospital of Xinjiang Medical University

InterventionalRandomisedSingle-centreOpen-labelControlled

Cell Therapy(Natural Killer (NK) cells)

Standard treatment + NK cells InfusionvsStandard treatment only

Infusion of NK cells 0.1-2x10e7 NK cells/kg twice a week (IV)

Improvement of clinical symptoms including duration of fever [Time Frame: Measured from day 0 through day 28 ]Evaluation of pneumonia improvementImprovement of clinical symptoms including respiratory frequency [Time Frame: Measured from day 0 through day 28]Evaluation of pneumonia improvementNumber of participants with treatment-related adverse events evaluated with CTCAE, version 4.0 [Time Frame: Measured from day 0 through day 28]Safety evaluation

18-65y.o.

44. A Pilot Clinical Study on Inhalation of Mesenchymal Stem

CHINA,Shanghai Public Health


Cell Therapy(Exosomes from Allogenic

Standard treatment + MSCs-derived exosomes

MSCs-derived exosomes

Adverse reaction (AE) and severe adverse reaction (SAE)

18-75y.o.











Cells Exosomes Treating Severe Novel Coronavirus Pneumonia (https://clinicaltrials.gov/ct2/show/NCT04276987) NCT04276987

Clinical CenterWuhan Jinyintan Hospital

Single-centreOpen-label

Adipose Mesenchymal Stem Cells (MSCs))

vsStandard treatment only

aerosol inhalation at Day 1, Day 2, Day 3, Day 4, Day 5 (2x10e8 nano vesicles/3 mL) (INH)

[Time Frame: Up to 28 days]Safety evaluation within 28 days after first treatment, including frequency of adverse reaction (AE) and severe adverse reaction (SAE)Time to clinical improvement (TTIC) [Time Frame: Up to 28 days]Efficiency evaluation within 28 days, including time to clinical improvement (TTIC)

45. Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia (https://clinicaltrials.gov/ct2/show/NCT04273646) NCT04273646

CHINA,Wuhan Union Hospital

InterventionalRandomisedOpen-labelPlacebo-controlled

Cell Therapy(Human Umbilical mesenchymal stem cells (HUMSCs))

Standard treatment + HUMSCs InfusionvsStandard treatment + Placebo

Infusion of HUMSCs at Day 1, Day 3, Day 5, Day7 (0.5x10e6 /kg) (IV)

Pneumonia severity index (PSI) [Time Frame: From Baseline (0W) to 12 week after treatment]Evaluation of Pneumonia ImprovementOxygenation index (ratio of partial pressure arterial oxygen and fraction of inspired oxygen-PaO2/FiO2) [Time Frame: From Baseline (0W) to 12 week after treatment]Evaluation of Pneumonia Improvement

18-65y.o.

46. Umbilical Cord (UC)-Derived Mesenchymal Stem Cells (MSCs) Treatment for the 2019-novel Coronavirus (nCOV) Pneumonia (https://clinicaltrials.gov/ct2/show/NCT04269525) NCT04269525

CHINA,Zhongnan Hospital of Wuhan University

InterventionalSingle-armSingle-centreOpen-label

Cell Therapy(Human Umbilical mesenchymal stem cells (HUMSCs))

Standard treatment + HUMSCs Infusion

Infusion of HUMSCs at Day 1, Day 3, Day 5, Day 7 (3 bags of 3.3x10e7 cell number/50ml/bag/time.) (IV)

Oxygenation index [Time Frame: on the day 14 after enrolment]Partial arterial oxygen pressure (PaO2) / oxygen concentration (FiO2)

18-75y.o.

47. Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus (https://clinicaltrials.gov/ct2/show/NCT04252118) NCT04252118

CHINA, Beijing 302 HospitalInnovative Precision Medicine Group (IPM),Wuhan Huoshenshan Hospital, Tianjin Haihe Hospital, Shenzhen Third People's Hospital,Fifth Affiliated Hospital, Sun Yat-Sen University

InterventionalNon-randomisedOpen-labelMulticentreControlled

Cell Therapy(Mesenchymal stem cells (HUMSCs))

Standard treatment + MSCs Infusion vsStandard treatment only

Infusion of MSCs at Day 0, Day 3, Day 6 (3x10e7 MSCs/time). (IV)

Size of lesion area by chest radiograph or CT [Time Frame: At Baseline , Day 3, Day 6, Day 10, Day 14, Day 21, Day 28]Evaluation of Pneumonia ImprovementSide effects in the MSCs treatment group [Time Frame: At Baseline , Day 3, Day 6, Day 10, Day 14, Day 21, Day 28, Day 90 and Day 180]Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

18-70y.o.

48. Umbilical cord mesenchymal stem cells (hucMSCs) in the treatment of high risk novel coronavirus pneumonia (COVID-19) patientsChiCTR2000030300

CHINA,Nanjing Second Hospital

Interventional Single-centre Single-arm

Cell TherapyHuman Umbilical mesenchymal cells (HUMSCs)

Infusion of Human Umbilical mesenchymal cells (HUMSCs)

N/A Time to disease recoveryMeasure time point of outcome: Time and rate of coronavirus become negativeExacerbation (transfer to Respiratory Intensive Care Unit) time

18-75y.o.

49. A study for the key technology of mesenchymal stem cells exosomes atomization in the treatment of

CHINA,Wuxi Fifth People's Hospital


Cell TherapyExosomes from Mesenchymal stem cell

Aerosol inhalation of mesenchymal stem cell exosomes

N/A Lung Computed Tomography. 18-65y.o.














novel coronavirus pneumonia (COVID-19) ChiCTR2000030261

vsNo intervention

50. Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration ChiCTR2000030173

CHINA,Nanhua Hospital


Cell TherapyHuman Umbilical mesenchymal stem cells (HUMSCs)

HUMSCs injectionvsStandard treatment

N/A Pulmonary function, Novel coronavirus pneumonic nucleic acid test.

18-60y.o.

51. Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19) ChiCTR2000030138

CHINA,Hainan Medical University


Cell TherapyHuman mesenchymal stem cells (HMSCs)

Standard treatment + MSCs injection vsStandard treatment + Placebo

N/A Clinical index. 16-75y.o.

52. Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19)ChiCTR2000030116

CHINA,The First Affiliated Hospital of Nanchang University

Interventional Randomised

Cell TherapyHuman umbilical cord mesenchymal stem cells (HUMSCs)

2 different doses of HUMSCs

N/A Time to leave ventilator on day 28 after receiving MSCs infusion.

18-75y.o.

53. Umbilical cord Wharton's Jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19) ChiCTR2000030088

CHINA,The Sixth Medical Center of PLA General Hospital, The 5th medical center of PLA general hospital


Cell TherapyHuman umbilical Wharton's Jelly derived mesenchymal stem cells (WJ-HUMSCs)

WJ-HUMSCs injectionvs Placebo

WJ-HUMSCs: 1x10e6/kg (IV)

The nucleic acid of the novel coronavirus is negative, Computed Tomography scan of ground glass shadow disappeared.

18-80y.o.

54. The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID-19)ChiCTR2000030020

CHINA,Second Hospital of University of South China, Hengyang



HUMSCs injection N/A Coronavirus nucleic acid markers negative rateMeasure time point of outcome: every dayMeasure method: Nucleic acid test reagentSymptoms improved after 4 treatmentsInflammation (Computed Tomography of the chest)

18-70y.o.

55. Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus pneumonia (COVID-19) ChiCTR2000029990

CHINA,Beijing Youan Hospital, Wuhan PuRen Hospital, Shanghai Guanghua integrated traditional Chinese and Western Medicine Hospital

Interventional RandomisedMulticentrePlacebo-controlled


HUMSCs injectionvsPlacebo

N/A Improved respiratory system function (blood oxygen saturation) recovery time.

18-95y.o.

56. Clinical Study for Human Menstrual Blood-Derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)ChiCTR2000029606

CHINA,The First Affiliated Hospital, College of Medicine, Zhejiang University


Cell Therapy(Menstrual Blood-Derived Stem Cells)Adjuvant Device(Artificial Liver)

Standard treatment + Menstrual Blood-Derived Stem Cells (IV)vsStandard treatment onlyvsStandard treatment + Artificial Liver TherapyvsStandard treatment + Menstrual Blood-Derived Stem Cells (IV) + Artificial Liver Therapy

N/A Mortality in patients. 1-99y.o.
























57. A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure (https://www.clinicaltrials.gov/ct2/show/NCT04319731 ) NCT04319731

UNITED STATES University of Utah

InterventionalSingle-armOpen-label

Cell Therapy(Amniotic Fluid)

Amniotic Fluid Inhalation Acute care: 3 ml (NEB) for 5daysICU: 3 ml (NEB) for 5 days + 6 ml (IV).

Ventilator Free Days [Time Frame: Measured from hospital admission day 60 after admission]Days alive and off mechanical ventilation at day 60. Measured only among patients who receive invasive mechanical ventilation.Duration of supplemental oxygen use [Time Frame: Measured from hospital admission to day 60]Duration from hospital admission until cessation of supplemental oxygen use. Measured only among patients who do not receive invasive mechanical ventilation.

≥18y.o.

58. Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically novel coronavirus pneumonia(COVID-19): a randomized controlled clinical trial ChiCTR2000029572

CHINA,Xiangyang First People's Hospital


Cell Therapy(Human Umbilical Mononuclear cells)

Standard treatment + Human Umbilical Mononuclear cells (IV)vsStandard treatment only

N/A Pneumonia Severity Index (PSI). ≥18y.o.

59. Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a Randomised controlled trial ChiCTR2000029569

CHINA,Xiangyang 1st People's Hospital


Cell Therapy(Human Umbilical Mononuclear cells conditioned medium)

Standard treatment + Human Umbilical Mononuclear cells conditioned medium vsStandard treatment

N/A Pneumonia Severity Index (PSI). ≥18y.o.

60. Clinical study for ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19) ChiCTR2000030165

CHINA,Haihe hospital


Cell Therapy(Ozonated autohaemotherapy)

Standard treatment + Ozonated Autohaemotherapy (mild and severe/critically ill groups)vsStandard treatment

N/A Chest Computed TomographyWhole blood cell analysisRecovery rateOxygenation indexInflammatory response index

18-80y.o.

61. A multicenter randomized controlled trial for ozone autohemotherapy in the treatment of novel coronavirus pneumonia (COVID-19) ChiCTR2000030102

CHINA,Tianjin Huanhu Hospital, Enshi Central Hospital, Zhongnan Hospital

Interventional MulticentreRandomisedControlled


Standard treatment + Ozonated Autohaemotherapy (common and severe, critical pneumonia groups)vsStandard treatment only

N/A Chest imagingMeasure time point of outcome: Before and after ozone treatmentRNA test of COVID-19Measure time point of outcome: Before and after ozone treatmentTime to remission/disappearance of primary symptoms: defined as the number of days when the three main symptoms of fever, cough, and shortness of breath are all relieved / disappearedCompletely antipyretic time: completely antipyretic was defined as the body temperature return to normal for over 24 hours.

18-80y.o.















Blood oxygen saturationTime to 2019-nCoV Reverse Transcription-Polymerase Chain Reaction negativity: defined as the last test time for two consecutive negative respiratory viral nucleic acid tests (sampling interval of at least 1 day)Liver, renal and heart function

62. A randomized controlled trial for the efficacy of ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)ChiCTR2000030006

CHINA,Union Hospital



Standard treatment + Ozonated AutohaemotherapyvsStandard treatment

N/A Recovery rate. N/A

63. HUMSCs and Exosomes Treating Patients with Lung Injury following Novel Coronavirus Pneumonia (COVID-19) ChiCTR2000030484

CHINA, Hubei Shiyan Taihe hospital


Cell TherapyHuman Umbilical mesenchymal stem cells (HUMSCs)& Exosomes

HUMSCs vs HUMSCs and Exosomes vs Placebo

HUMSCs: 5x10e7 cells/time, once/week, twice/course, 2 courses in total (IV)Exosomes:180mg /time/day, 7 days/course, 2 courses in total (IV)

Ratio of partial pressure arterial oxygen and fraction of inspired oxygen (PaO2/FiO2) or respiratory rate (without oxygen)Frequency of respiratory exacerbationObserve physical signs and symptoms and record clinical recovery timeThe number and range of lesions indicated by Computed Tomography and X-ray of lungTime for cough to become mild or absentTime for dyspnea to become mild or no dyspneaFrequency of oxygen inhalation or non-invasive ventilation, frequency of mechanical ventilationInflammatory cytokines (C-reactive protein / Procalcitonin / Serum amyloid A, etc.)Frequency of serious adverse events

18-70y.o.

64. Clinical Study of Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells (https://clinicaltrials.gov/ct2/show/NCT04302519 ) NCT04302519

CHINA,CAR-T (Shanghai) Biotechnology Co., Ltd.

Interventional Single-armOpen -label

Cell therapy(Dental pulp Mesenchymal Stem Cells)

Injection of dental mesenchymal stem cells + Standard treatment

Dental mesenchymal stem cells: 1x10e6 cells/kg (IV) on day 1, 3 and 7

Disappear time of ground-glass shadow in the lungs [Time Frame: 14 days]Kaplan-meier method was used to calculate the median glassy shadow time in all subjects

18-75y.o.

65. Clinical Application of Stem Cell Educator Therapy for the Treatment of Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (https://www.clinicaltrials.gov/ct2/show/NCT04299152 )

UNITED STATESTianhe Stem Cell Biotechnologies Inc.

Interventional Single-centreRandomisedSingle-blindedControlled

Cell therapy(Stem Cell Educator-Treated Mononuclear Cells Apheresis)

Stem cell educator therapy vs Standard treatment (addressing symptoms such as fever and cough)

N/A Determine the number of Covid-19 patients who were unable to complete SCE Therapy [Time Frame: 4 weeks]The feasibility will be evaluated by the number of Covid-19 patients who were unable to complete SCE Therapy.

18-60y.o.











NCT0429915266. Treatment of COVID-19 Patients

Using Wharton's Jelly-Mesenchymal Stem Cells (https://clinicaltrials.gov/ct2/show/NCT04313322 ) NCT04313322

JORDAN, Stem Cells Arabia

Interventional Single-arm Open-label

Cell Therapy(Human umbilical Wharton’s Jelly derived mesenchymal stem cells WJ-HUMSCs)

WJ-MSCs injection WJ-MSC: 3 doses of 1x10e6/kg (IV)

Clinical outcome [Time Frame: 3 weeks]Improvement of clinical symptoms including duration of fever, respiratory distress, pneumonia, cough, sneezing, diarrhoea.Computed Tomography Scan [Time Frame: 3 weeks]Side effects measured by Chest RadiographRT-PCR results [Time Frame: 3 weeks ]Results of Real-Time Polymerase Chain Reaction of Viral RNA, Turing negative

≥18y.o.

67. Clinical study for the efficacy of Mesenchymal stem cells (MSC) in the treatment of severe novel coronavirus pneumonia (COVID-19) (http://www.chictr.org.cn/showprojen.aspx?proj=51050 ) ChiCTR2000030835

CHINA The First Affiliated Hospital of Xinxiang Medical University, The First Affiliated Hospital of Zhengzhou University, Henan people's Hospital, the first people's hospital in Zhenghzou

InterventionalNon-randomised MulticentreParallel-controlled

Cell Therapy (Mesenchymal Stem Cells)

High Dose MSC + Standard Treatment vs Low Dose MSC + Standard Treatment

High Dose MSC:2x10e6 / kg / time (IV)Low Dose MSC:1x10e6 / kg / time (IV)

After MSc cell infusion, the time for patients to reach the standard of isolation and discharge.

18-75y.o.

68. NestCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia (https://clinicaltrials.gov/ct2/show/NCT04315987 ) NCT04315987

BRASIL, Hospital Vera Cruz

Interventional Non-randomised Single-arm Open-label 2-Phases

Cell Therapy (Mesenchymal Stem Cells)

NestCell® + standard treatment

Phase 1: standard treatment + 3x1x10e6 cells /kg NestCell® (IV) on Day1, 3, 7Phase 2: After Safety Monitoring Board evaluation, the dose and posology recommended by Board.

Change in Clinical Condition [Time Frame: 10 days]Ordinal scale (WHO ordinal scale that measures illness severity over time)

≥18y.o.

69. Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy severe novel coronavirus pneumonia (COVID-19)ChiCTR2000030179


Interventional RandomisedSingle-centre Controlled

Convalescent Plasma Standard treatment + Convalescent Plasma vsStandard treatment

N/A Cure rate, Mortality. 18-65y.o.

70. A single arm trial to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19)ChiCTR2000030046

CHINA,First People's Hospital of Jiangxia District, Wuhan (Union Jiangnan Hospital), Wuhan Jinyintan Hospital, The integrated traditional Chinese and western medicine hospital of Jiangxia district

Interventional Single-armOpen-labelControlled

Convalescent Plasma Standard treatment + Inactivated Convalescent Plasma

N/A The changes of clinical symptom, laboratory and radiological dataMeasure time point of outcome: 3 days after convalescent plasma transfusionOxyhemoglobin saturation.DyspnoeaBody temperatureRadiological characteristic signBlood routine

18-80y.o.













C-reaction proteinLymphocyte countLiver function:TBIL(total bilirubin), AST(alanine aminotransferase) and ALT(aspartate aminotransferase)Neutralisation antibody level

71. Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19) ChiCTR2000030039

CHINA,Affiliated Hospital of Xuzhou Medical University

Interventional RandomisedSingle-centreControlled


Convalescent Plasma:200-500ml (two infusions recommended)

SARS-CoV-2 DNAMeasure time point of outcome: Infusion day1 and recheck according to the patient's conditionSARS-CoV-2 antibody levelsMeasure time point of outcome: Infusion day1 and recheck according to the patient's conditionThoracic spiral Computed TomographyMeasure time point of outcome: Hospitalized day1, day 3, day 7, day 14, Infusion day1, recheck according to the patient's condition,14 days after discharge

≥18y.o.

72. A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19) ChiCTR2000030010

CHINA,Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)

Interventional RandomisedDouble-blindControlled

Convalescent Plasma Standard treatment + Inactivated Convalescent Plasma vsStandard treatment

N/A Improvement of clinical symptoms (Clinical improvement is defined as a reduction of 2 points on the 6-point scale of the patient's admission status or discharge from the hospital)

≥18y.o.

73. Study on convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19) ChiCTR2000029850

CHINA,The First Affiliated Hospital of Zhejiang University School of Medicine



N/A Fatality rate. 16-99y.o.

74. Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19 (https://clinicaltrials.gov/ct2/show/NCT04292340) NCT04292340


ObservationalProspectiveSingle-arm

Convalescent Plasma Convalescent Plasma N/A The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 1 [Time Frame: 1 day after receiving plasma transmission]The SARS-CoV-2 nucleic acid was quantified using Reverse Transcription Polymerase Chain ReactionThe virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3 [Time Frame: 3 days after receiving plasma transmission]The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7 [Time Frame: 7 days after

All ages












receiving plasma transmission]Numbers of participants with different Clinical outcomes [Time Frame: From receiving plasma transmission to 4 weeks]Clinical outcomes include death, critical illness, recovery

75. A randomized, double-blind, parallel-controlled trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia (COVID-19) (http://www.chictr.org.cn/showprojen.aspx?proj=50696 ) ChiCTR2000030929

CHINA, Renmin Hospital of Wuhan University

Interventional RandomisedDouble-blindParallel-controlled

Convalescent Plasma Anti-SARS-CoV-2 virus inactivated plasmavsOrdinary Plasma

N/A Improvement of clinical symptoms(Clinical improvement is defined as a reduction of 2 points on the 6-point scale of the patient's admission status or discharge from the hospital)

18-70y.o.

76. Hyperimmune Plasma for Critical Patients With COVID-19 (COV19-PLASMA) (https://clinicaltrials.gov/ct2/show/NCT04321421 ) NCT04321421

ITALY, Foundation IRCCS San Matteo Hospital

Interventional Single-arm Open-label

Convalescent Plasma Convalescent Plasma N/A Death [Time Frame: within 7 days]Death from any cause

≥18y.o.

77. Convalescent plasma for the treatment of severe and critical novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial ChiCTR2000029757

CHINA,12 sites

Interventional Randomised Controlled Multicentre

Convalescent Plasma Convalescent Plasma + standard treatmentvsStandard treatment

N/A The number of days between randomised grouping and clinical improvementMeasure time point of outcome: within 28 days admissionMeasure method: Clinical improvement is defined as the patient's admission status of 6 grade scale score reduced by 2 points or discharged.

≥18y.o.

78. Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients NCT04264858

CHINADepartment of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei

InterventionalNon-RandomizedOpen-label

Convalescent Plasma(Immunoglobulin of cured patients)Intravenous Immunoglobulin

Immunoglobulin of cured patientsvsIntravenous Immunoglobulin

Immunoglobulin of cured patients: 0.2g/kg, IV drip once daily for 3 daysIVIG: 0.2g/kg, IV drip once daily for 3 days

TTCI [Time Frame: up to 28 days]TTCI is defined as the time (in days) from initiation of study treatment (active or placebo) until a decline of two categories from admission status on a six-category ordinal scale of clinical status which ranges from 1 (discharged) to 6 (death). Six-category ordinal scale: 6. Death; 5. ICU, requiring ECMO and/or IMV; 4. ICU/hospitalisation, requiring NIV/ HFNC therapy; 3. Hospitalisation, requiring supplemental oxygen (but not NIV/ HFNC); 2. Hospitalization, not requiring supplemental oxygen; 1. Hospital discharge. Abbreviation: IMV, invasive mechanical ventilation; NIV, non-invasive mechanical

≥18y.o.

https://clinicaltrials.gov/ct2/show/NCT04264858?term=NCT04264858&draw=2&rank=1










ventilation; HFNC, High-flow nasal cannula.

79. A randomized, open-label study to evaluate the efficacy and safety of low-dose corticosteroids in hospitalized patients with novel coronavirus pneumonia (COVID-19) ChiCTR2000029656

CHINA,Wuhan Pulmonary Hospital


Corticosteroids Standard treatment +low dose Methylprednisolone (IV)vsStandard treatment

N/A Electrocardiogram, Chest imaging, Complications, Vital signs, National Early Warning Score (NEWS) 2.

≥18y.o.

80. Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: a randomized controlled trialChiCTR2000029386

CHINA,Chongqing Public Health Medical Center


Corticosteroids Standard treatment + Methylprednisolone (IV)vsStandard treatment

Methylprednisolone: 1-2mg/kg OD (IV) for 3 days

Sequential Organ Failure Assessment (SOFA) Score.

>18y.o.

81. Efficacy and Safety of Corticosteroids in COVID-19 (https://clinicaltrials.gov/ct2/show/NCT04273321) NCT04273321

CHINA, Beijing Chao Yang Hospital

Interventional RandomisedOpen-label Single-centreControlled

Corticosteroids Standard treatment + Methylprednisolone vsStandard treatment only

Methylprednisolone 1mg/kg OD (IV) for 7 days

The incidence of treatment failure in 14 days [Time Frame: 14 days]The clinical symptoms and signs continue to deteriorate, or new pulmonary or extrapulmonary lesions appear, or the chest imaging indicates the progress, and the patient is transferred to Intensive Care Unit or intubation and invasive ventilation or died.

≥18y.o.

82. Glucocorticoid Therapy for Novel Coronavirus Critically Ill Patients With Severe Acute Respiratory Failure (Steroids-SARI) (https://clinicaltrials.gov/ct2/show/NCT04244591) NCT04244591

CHINA,Zhongnan HospitalRenmin Hospital of Wuhan University


Corticosteroids Standard treatment + Methylprednisolone vsStandard treatment only

Methylprednisolone 40 mg BID (IV) for 5 days

Lower Murray lung injury score [Time Frame: 7 days after randomisation]Murray lung injury score decreased more than one point means better outcome. The Murray scoring system range from 0 to 16 according to the severity of the condition.Lower Murray lung injury score [Time Frame: 14 days after randomisation]Murray lung injury score decreased more than one point means better outcome. The Murray scoring system range from 0 to 16 according to the severity of the condition.

≥18y.o.

83. The clinical value of corticosteroid therapy timing in the treatment of novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial ChiCTR2000030481

CHINA, Zhongnan Hospital of Wuhan University, Wuhan Central Hospital, Wuhan Seventh Hospital


Corticosteroids Early corticosteroids vs Middle-late corticosteroidsvsNo corticosteroids

N/A The time of duration of COVID-19 nucleic acid Reverse transcription polymerase chain reaction (RT-PCR) test results of respiratory specimens (such as throat swabs) or blood specimens change to negative.

>18y.o.

84. A clinical research for the changes of Blood cortisol ACTH level and adrenal morphology in blood cortisol to guide the application of individualized hormone in severe novel coronavirus pneumonia (COVID-19) patients



Corticosteroids Patients receiving Standard treatment + Corticosteroids

N/A Cortisol, Adrenocorticotropic hormone (ACTH), Form of Adrenal tissue

≥18y.o.

















ChiCTR200003011585. Efficacy of Methylprednisolone for

Patients With COVID-19 Severe Acute Respiratory Syndrome (MP-C19)(https://www.clinicaltrials.gov/ct2/show/NCT04323592 ) NCT04323592

ITALY,University of Trieste

InterventionalNon-randomised Parallel-controlled

Corticosteroids Methylprednisolone + Standard treatmentvsStandard treatment

Methylprednisolone: initial 80 mg bolus (IV), followed by 80 mg at 10ml/h speed for 7 days (IV)

Composite primary end-point [Time Frame: 28 days]Death or Intensive Care Unit admission or Invasive mechanical ventilation (yes/not, at least one of three of the composite end-point)Death [Time Frame: 28 days]Yes/noAdmission to Intensive Care Unit [Time Frame: 28 days]Yes/noEndotracheal intubation (invasive mechanical ventilation) [Time Frame: 28 days]Yes/no

18-80y.o.

86. The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia NCT04263402

CHINA,Department and Institute of Infectious Disease, Wuhan, Hubei

InterventionalRandomisedParallel-controlledSingle-blind

Corticosteroids Methylprednisolone low dosevsMethylprednisolone high dose

Methylprednisolone <40mg/d IV drip for 7 days or 40-80mg/d IV drip for 7 days

Rate of disease remission [Time Frame: day 7]For mild patients: disease remission refers to relieved symptoms with improved lung Computed Tomography (CT); For severe patients: disease remission refers to relieved symptoms with improved lung CT; or SPO2>93% or Ratio of partial pressure arterial oxygen and fraction of inspired oxygen (PaO2/FiO2) >300mmHg.Rate and time of entering the critical stage [Time Frame: day 7]The critical stage refers to respiratory failure that occurs and requires mechanical ventilation, shock, or having other organ failure that needs Intensive Care Unit monitoring and treatment.

≥18y.o.

87. A randomized, parallel controlled trial for the efficacy and safety of Sodium Aescinate Injection in the treatment of patients with pneumonia (COVID-19) ChiCTR2000029742

CHINA,Tongji Hospital,Tongji Medical College, Huazhong University of Science and Technology


Corticosteroids Other agents(Sodium Aescinate)

Sodium Aescinate + Standard treatmentvsCorticosteroids + Standard treatmentvsStandard treatment

N/A Chest imaging. 18-70y.o.

88. Clinical study for individualized nutritional assessment and supportive treatment of novel coronavirus pneumonia (COVID-19) patients in Tibetan Plateau ChiCTR2000030260

CHINA,Ganzi Hospital of West China Hospital, Sichuan University


Dietary and Supportive Measures

Enteral Nutritional Emulsion (TPF-T)vsNo Intervention

Enteral Nutritional Emulsion (TPF-T): 200mL BID

The Nutrition Risk Screening 2002 (NRS-2002), Body Mass Index (BMI), Triceps skinfold thickness (TSF), Prealbumin, Total albumin, Leucocyte count, C-reactive protein (CRP), Lymphocyte percentage, Tumour necrosis factor alpha, Interleukin 6

N/A












89. A clinical study for probiotics in the regulation of intestinal function and microflora structure of novel coronavirus pneumonia (COVID-19) ChiCTR2000029999

CHINA,Shanghai 10th people's hospital, Shanghai public health clinical center, Wuhan third people's hospital

Interventional Randomised


Mild group + ProbioticsvsSevere group + Probiotics

N/A Gut microbiome, faecal metabolomics, blood routine, albumin, serum potassium, C-reactive protein, alanine aminotransferase, aspartate aminotransferase, urea, creatinine, urea nitrogen, D-Dimer, erythrocyte sedimedation rate, IgG, IgM, IgA, hepatitis B surface antigen, β2-microglobulin, Interferon-gamma, Interleukin (IL)-6, TNF-beta, IL-10, IL-2, IL-4, IL-13, IL-12, chest Computed Tomography (CT), abdominal CT, ECG, weight, height, body temperature, respiratory rate, heart rate, blood pressure, defecate frequency, Bristol grading

18-100

90. A prospective, multicenter, open-label, randomized, parallel-controlled trial for probiotics to evaluate efficacy and safety in patients infected with 2019 novel coronavirus pneumonia (COVID-19) ChiCTR2000029974

CHINA,Shandong Province Chest Hospital, Jinan Infectious Disease Hospital, Jining Infectious Disease Hospital, Qingdao Chest Hospital, Yantai Qishan hospital, Linyi People's Hospital, Liaocheng infectious disease hospital, Weifang People's Hospital, Zibo Infectious Diseases hospital, Rizhao People's Hospital, Weihai Chest Hospital, Affiliated Hospital of Qingdao University

Interventional MulticentreOpen-label RandomisedControlled


Standard treatment + Live Clostridium Butyricum Capsules + Live Bacillus Coagulans Tabletsvs Standard treatment

Live Clostridium Butyricum Capsules and Live Bacillus Coagulans Tablets for 14 days(dose N/A)

Time to Clinical recovery, Butyrate in faeces.

≥18y.o.

91. A multicenter, randomized controlled trial for the efficacy and safety of Alpha lipoic acid (iv) in the treatment of patients of severe novel coronavirus pneumonia (COVID-19) ChiCTR2000029851

CHINA,Wuhan Jinyintan Hospital, Renmin's Hospital of Wuhan University, Tongji Hospital

Interventional MulticentreRandomisedPlacebo-controlled


Standard treatment + Alpha lipoic acid (IV)vs Standard treatment + Placebo

N/A Sequential Organ Failure Assessment (SOFA) Score.

35-74y.o.

92. Application of Regulating Intestinal Flora in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19) ChiCTR2000029849

CHINA,The First Affiliated Hospital of Zhengzhou University

Interventional Randomised Controlled


Standard treatment + Regulating intestinal floravs Standard treatment

N/A Length of admission, mortality rate.

18-75y.o.

93. A randomized, open, controlled trial for diammonium glycyrrhizinate enteric-coated capsules combined with vitamin C tablets in the treatment of common novel coronavirus pneumonia




Standard treatment + Diammonium Glycyrrhizinate Enteric-coated Capsules + Vitamin C tablets vs

Diammonium Glycyrrhizinate Enteric-coated Capsules: 150mg TID (PO)Vitamin C: 0.5g

Time to Clinical recovery. 18-75y.o















(COVID-19) in the basic of clinical standard antiviral treatment to evaluate the safety and efficiency ChiCTR2000029768

Standard treatment OD (PO)

94. To evaluate the efficacy and safety of diammonium glycyrrhizinate enteric-coated capsules combined with hydrogen-rich water in the treatment of novel coronavirus pneumonia (COVID-19) (http://www.chictr.org.cn/showprojen.aspx?proj=50487 ) ChiCTR2000030490

CHINA,Changhai Hospital, Shanghai



Diammonium glycyrrhizinate enteric-coated capsule combined with hydrogen-rich water

N/A Cure rate. 18-75y.o.

95. Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia (https://clinicaltrials.gov/ct2/show/NCT04264533) NCT04264533




Vitamin C infusionvsPlacebo

Vitamin C infusion 24g/day for 7 days with a speed of 7ml/h (IV)

Ventilation-free days [Time Frame: on the day 28 after enrolment]Days without ventilation support during 28 days after patients' enrolment

≥18y.o.

96. Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool (https://clinicaltrials.gov/ct2/show/NCT04274322) NCT04274322

CHINA, Peking University Third Hospital

Prospective Observational study


Nutrition support with calories and proteins are given to patients by using ways as parenteral nutrition, enteral nutrition, oral nutrition supplement according to high or low NUTRIC score

N/A 28-day all cause mortality [Time Frame: from admission to 28-day/discharge, an average of length of ICU stay is 28-day].

≥18y.o.

97. Metabolic abnormalities and rearrangement reversal treatment of patient with novel coronavirus pneumonia (http://www.chictr.org.cn/showprojen.aspx?proj=51194 ) ChiCTR2000031271

CHINA, The Third Affiliated Hospital of Sun Yat-sen University



Compound amino acid combined with routine treatmentvsStandard treatment

N/A Hospital stay or death ratio of experimental group / death ratio of control group.

18-65y.o.

98. Evaluation of the effect of taking tricholoma matsutake, cannabis sativa capsule and dendrobium candidum to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19) during convalescence. (http://www.chictr.org.cn/showprojen.aspx?proj=51194 ) ChiCTR2000030920




Taking tricholoma matsutakevsTaking cannabis sativa capsulevsTaking dendrobium candidumvsTaking routine drugs and food

N/A Albumin, Cellular immune indicators (total lymphocyte count (TLC) and T lymphocyte subsets (CD3, CD4)).

≥18y.o.

99. Evaluation of the effect of taking Newgen beta-gluten probiotic composite powder to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19) (http://www.chictr.org.cn/showpr

CHINA HwaMei Hospital, University of Chinese Academy of Sciences, Zhejiang



Newgen beta-gluten probiotic composite powder Vs Routine medicines and food

N/A Serum albumin, Siderophilin, Prealbumin, Lung Computed Tomography scanning result.

N/A














ojen.aspx?proj=50462 ) ChiCTR2000030897

100. Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus(https://www.clinicaltrials.gov/ct2/show/NCT04323345 ) NCT04323345

EGYPT,Misr University for Science and Technology



Honey + Standard treatmentVsStandard treatment

Honey: 1 mg/kg per day for 14 days

Rate of recovery from positive to negative swaps [Time Frame: 14 days]Percentage of patients turned from positive to negative swaps at day 14Fever to normal temperature in days [Time Frame: 14 days]Number of days till no feverResolution of lung inflammation in Computed Tomography or X ray [Time Frame: 30 days ]Number of days till lungs recovery in chest X ray or CT

5-75y.o.

101. A multicenter, randomized, double-blind, controlled clinical trial for leflunomide in the treatment of novel coronavirus pneumonia (COVID-19) ChiCTR2000030058

CHINA,Renmin Hospital of Wuhan University, Zhongnan Hospital of Wuhan University, The Third Hospital of Wuhan City


Disease-modifying anti-rheumatic drug(Leflunomide)

Standard treatment + Leflunomide (PO)vsStandard treatment

N/A The days from positive to negative for viral nucleic acid testing.

18-70y.o.

102. A multicenter, randomized, controlled trial for efficacy and safety of hydrogen inhalation in the treatment of novel coronavirus pneumonia (COVID-19) patients ChiCTR2000030258

CHINA,The Fourth Affiliated Hospital of Harbin Medical University, Harbin infectious diseases hospital, Harbin Chest Hospital, Heilongjiang Provincial Institute of infectious diseases


Inhaled Gases(Hydrogen)

Standard treatment + Hydrogen inhalationvsStandard treatment

N/A Temperature, Respiratory rate, Blood oxygen saturation, cough symptom, Lung Computed Tomography, Fatality rate.

18-70y.o.

103. A Multicenter, Randomized, Parallel Controlled Clinical Study of Hydrogen-Oxygen Nebulizer to Improve the Symptoms of Patients With Novel Coronavirus Pneumonia (COVID-19) ChiCTR2000029739

CHINA,The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Eighth People's Hospital, Shanghai Public Health Clinical Center


Inhaled Gases(Hydrogen)

Hydrogen-Oxygen NebulizervsOxygen concentrator

N/A The condition worsens and develops into severe or critical condition, the condition improves significantly and reaches the discharge standard, the overall treatment time is no longer than 14 days.

18-85y.o.

104. Nitric Oxide Gas Inhalation Therapy for Mechanically Ventilated Patients With Severe Acute Respiratory Syndrome Caused by 2019-nCoV (https://clinicaltrials.gov/ct2/show/NCT04306393 ) NCT04306393

UNITED STATES, CHINA, ITALYMassachusetts General HospitalXijing HospitalFondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoNiguarda Hospital

Interventional MulticentreRandomisedControlledSingle-blind

Inhaled Gases (Nitric oxide)

Inhalation of nitric oxide vs Placebo

80 ppm of inhaled nitric oxide for 48 hours, followed by 40 ppm, followed by weaning before stop.

Weaning criteria: maintenance of a PaO2/FiO2 ratio >/= 300 for at least 24 hours consecutively

Change of arterial oxygenation at 48 hours from enrolment [Time Frame: 48 hours]Difference within groups in terms of Ratio of partial pressure arterial oxygen and fraction of inspired oxygen (PaO2/FiO2) ratio. If a patient dies during the first 48 hours of treatment, the last available blood gas analysis will be used.

18-99y.o.

105. Nitric Oxide Gas Inhalation UNITED STATES, Interventional Inhaled gases Inhalation of nitric oxide 20-30 minutes Reduction in the incidence of ≥18y.o.















Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID-19 Infection: a Randomized Clinical Trial (https://www.clinicaltrials.gov/ct2/show/NCT04305457?term=NCT04305457&draw=2&rank=1 ) NCT04305457

CHINA, ITALYMassachusetts General HospitalXijing HospitalFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

MulticentreRandomisedControlledOpen-Label

(Nitric oxide) vs Placebo

(INH) BID for 14 days, Targeted No inhaled concentration: 140-180 ppm. CPAP end-expiratory pressure 2-10 cmH2O or non-rebreathing mask without positive end-expiratory pressure, depending on the clinical needs of the patient

patients with mild/moderate COVID-19 requiring intubation and mechanical ventilation [Time Frame: 28 days]The primary outcome will be the reduction in the incidence of patients requiring intubation and mechanical ventilation, as a marker of deterioration from a mild to a severe form of COVID-19. Patients with indication to intubation and mechanical ventilation but concomitant DNI (Do Not Intubate) or not intubated for any other reason external to the clinical judgment of the attending physician will be considered as meeting the criteria for the primary endpoint.

106. A randomized controlled Trial for therapeutic efficacy of Recombinant Human Interferon alpha 1b Eye Drops in the treatment of elderly with novel coronavirus pneumonia (COVID-19)ChiCTR2000029989

CHINA,Central theater General Hospital Wuchang district, Central theater General Hospital Hankou district, Huoshenshan hospital

InterventionalMulticentre RandomisedPlacebo-controlled

Interferon Standard treatment + Recombinant Human Interferon alpha 1b Eye DropsvsStandard treatment + Placebo

N/A Arterial Blood Oxygen Saturation, Time to Clinical recovery (TTCR), Temperature, Respiratory rate, Lung Computed Tomography.

≥60y.o.

107. Clinical study of nebulized Xiyanping injection in the treatment of novel coronavirus pneumonia (COVID-19) ChiCTR2000029756



InterferonTraditional Chinese Medicine

Nebulised Xiyanping injectionvsInterferon

N/A Vital signs (Body temperature, blood pressure, heart rate, breathing rate), Respiratory symptoms and signs (lung sounds, cough, sputum), aetiology and laboratory testing, partial pressure arterial oxygen (PaO2)/ peripheral capillary oxygen saturation (SPO2), liquid balance, ventilator condition, imaging changes

18-60y.o.

108. Randomized, open, blank controlled trial for the efficacy and safety of recombinant human interferon alpha 1beta in the treatment of Wuhan patients with novel coronavirus pneumonia (COVID-19)Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients (https://clinicaltrials.gov/ct2/show/record/NCT04293887) ChiCTR2000030480, NCT04293887


Interventional RandomisedPlacebo-Controlled

Interferon Standard treatment + Cerrokin (recombinant human Interferon alpha 1beta) vsStandard treatment

Recombinant human Interferon alpha 1beta: 10UG BID x 10 days (NEB).

The incidence of side effects [Time Frame: Within 14 days after enrolment]DyspnoeaThe incidence of side effects [Time Frame: Within 14 days after enrolment]SPO2≤94%The incidence of side effects [Time Frame: Within 14 days after enrolment]Respiratory rate ≥24 breaths/min in oxygen state).

≥18y.o.

109. A randomised double-blind placebo-controlled trial to determine the safety and efficacy

UNITED KINGDOM,Synairgen Research Limited


Interferon Interferon beta-1avsPlacebo

Interferon beta-1a: 6 Million IU (NEB)

Change in condition measured using the Ordinal Scale for Clinical Improvement during the

≥18y.o.

https://clinicaltrials.gov/ct2/show/record/NCT04293887

https://clinicaltrials.gov/ct2/show/record/NCT04293887










https://www.clinicaltrials.gov/ct2/show/NCT04305457?term=NCT04305457&draw=2&rank=1



of inhaled SNG001 (IFNβ-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection (COVID-19) (https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB/) EudraCT Number: 2020-001023-14

dosing period.The Ordinal Scale for Clinical Improvement is a World Health Organisation recommended scale for use in COVID-19 trials. Time point(s) of evaluation of this end point: The dosing period is 14 days. Changes in the ordinal scale during the dosing period will be assessed.

110. A Multicenter, Randomized, Controlled trial for Recombinant Super-Compound Interferon (rSIFN-co) in the Treatment of 2019 Novel Coronavirus (2019-nCoV) Infected Pneumonia ChiCTR2000029638

CHINA, West China Hospital, Sichuan University, Chengdu Public Health Clinical Medical Center, Wuhan Red Cross Hospital, Sichuan provincial People's Hospital, the Affiliated Hospital of Southwest Medical University, Affiliated Hospital of North Sichuan Medical College, MianYang Central Hospital, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine

Interventional Randomised Controlled Multicentre

Interferon(Recombinant super-compound interferon (rSIFN-co))

Recombinant super-compound interferon (rSIFN-co) (NEB)vsInterferon α (NEB)

N/A Disease relief, Time to clinical improvement, Overall rates of clinical improvement assessed at days 7, 14, and 28, Time to chest Computed Tomography improvement, time to virus nucleic acid negative-conversion, overall rates of radiological improvement on days 7, 14, and 28, overall rates of virus nucleic acid negative-conversion on quantitative Reverse transcription polymerase chain reaction (qRT-PCR) in nasopharyngeal swabs samples on days 7, 14, and 28, serious adverse events

18-75y.o.

111. The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia (https://clinicaltrials.gov/ct2/show/NCT04261426) NCT04261426

CHINA,Peking Union Medical College Hospital

InterventionalRandomised Single-centreOpen-labelControlled

Intravenous Immunoglobulin

Intravenous Immunoglobulin infusion + standard treatment vsStandard treatment

Intravenous Immunoglobulin: 0.5g/kg/d for 5 days (IV)

Clinical improvement based on the 7-point scale [Time Frame: 28 days after randomisation]A decline of 2 points on the 7-point scale from admission means better outcome. The 7-category ordinal scale that ranges from 1 (discharged with normal activity) to 7 (death).Lower Murray lung injury score [Time Frame: 7 days after randomisation]Murray lung injury score decrease more than one point means better outcome. The Murray scoring system range from 0 to 4 according to the severity of the condition.- Lower Murray lung injury score [Time Frame: 14 days after randomisation]Murray lung injury score decrease more than one point means better outcome. The Murray scoring system range from 0 to 4 according to the severity of the condition

≥18y.o.






https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB/



112. Study for safety and efficacy of Jakotinib hydrochloride tablets in the treatment severe and acute exacerbation patients of novel coronavirus pneumonia (COVID-19)ChiCTR2000030170



Janus kinase inhibitor(Jakotinib)

Standard treatment + Jakotinib hydrochloride in severe groupvsStandard treatment + Jakotinib hydrochloride in acute axacerbation group

Jakotinib hydrochloride: 50mg or 100mg BID for 7 days

Severe group: Time to clinical improvement (TTCI) [time window: 28 days]Acute exacerbation novel coronavirus pneumonia group: Time to clinical recovery [time window: 28 days] and the ratio of common to severe and critically severe.

50-100y.o.

113. A prospective, single-blind, randomized controlled trial for Ruxolitinib combined with mesenchymal stem cell infusion in the treatment of patients with severe novel coronavirus pneumonia (COVID-19) ChiCTR2000029580

CHINA,Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Interventional RandomisedSingle-blindControlled

Janus kinase inhibitor(Ruxolitinib)Cell TherapyMesenchymal stem cells (MSCs)

Standard therapy + MSCs + RuxolitinibvsStandard treatment

N/A Safety. 18-75y.o.

114. Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients(https://www.clinicaltrials.gov/ct2/show/NCT04321993 ) NCT04321993

CANADA,Nova Scotia Health Authority Dalhousie University

Interventional Non-randomised Parallel-controlled

Janus kinase inhibitor (Baricitinib)Protease Inhibitor (Lopinavir/Ritonavir) Cytokine Antagonist (Sarilumab)Anti-malaria drug (Hydroxychloroquine)

Lopinavir/ritonavirvsHydroxychloroquine sulfatevsBaricitinibvsSarilumabvsStandard treatment

Lopinavir/ritonavir: 400/100mg BID (PO) for 10 daysHydroxychloroquine sulphate: 400 mg BID (PO) for 10 daysBaricitinib: 2 mg OD (PO) for 10 daysSarilumab: 200mg single dose (SC)

Clinical status of subject at day 15 (on a 7 point ordinal scale). [ Time Frame: Up to 15 days ]A) Not hospitalised, no limitations on activities B) Not hospitalized, limitation on activities; C) Hospitalised, not requiring supplemental oxygen; D) Hospitalised, requiring supplemental oxygen; E) Hospitalised, on non-invasive ventilation or high flow oxygen devices; F) Hospitalised, on invasive mechanical ventilation or ECMO; G) Death.

≥18y.o.

115. Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study (https://www.clinicaltrials.gov/ct2/show/NCT04320277 ) NCT04320277

ITALY, Hospital of Prato

InterventionalNon-randomised Open-labelControlled

Janus kinase inhibitor (Baricitinib)Protease Inhibitor (Ritonavir) Anti-malaria drug (Hydroxychloroquine)

Baricitinib + Ritonavir vsAntiviral and/or hydroxychloroquine.

Baricitinib: 4mg OD for 2 weeks (PO) Ritonavir: 600 mg BID for 2 weeks (PO)

The percentage of patients requiring transfer to ICU as compared with the rate of transfers observed in controls. [ Time Frame: 2 weeks ]The percentage of Intensive Care Unit admission in patients and controls will be compared for statistical difference

18-85y.o.

116. A randomized, parallel controlled open-label trial for the efficacy and safety of Prolongin (Enoxaparin Sodium Injection) in the treatment of adult patients with novel coronavirus pneumonia (COVID-19) (http://www.chictr.org.cn/showprojen.aspx?proj=50795 , http://www.chictr.org.cn/showprojen.aspx?proj=50786 ) ChiCTR2000030701, ChiCTR2000030700

CHINA,The Third People’s Hospital of Shenzhen Union Hospital affiliated to Tongji Medical College of Huazhong University

Interventional RandomisedParallel-controlled Open-label

Low-molecular weight heparin(Enoxaparin)

Standard treatment + Enoxaparin Sodium InjectionvsStandard treatment

N/A Time to Virus Eradication. ≥18y.o.

117. The efficacy and safety of CHINA, Interventional Macrolide Standard treatment + N/A Fever to normal time (day) [Time 18-75y.o.
















carrimycin treatment in patients with novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trialThe Clinical Study of Carrimycin on Treatment Patients With COVID-19 (https://clinicaltrials.gov/ct2/show/NCT04286503) ChiCTR2000029867, NCT04286503

Huangshi Central Hospital, First Affiliated Hospital of Chongqing Medical University, The Second Affiliated Hospital of Harbin Medical University, No.2 People's Hospital of Fuyang City, First Affiliated Hospital Bengbu Medical College, Renmin Hospital, The sixth people's hospital of Shenyang, Nanyang Central Hospital

MulticentreRandomisedOpen-labelControlled

(Carrimycin)Other antiviral(Umifenovir)Protease Inhibitor(Lopinavir/ritonavir)Anti-malaria Drug(Chloroquine)

CarrimycinvsStandard treatment + Lopinavir/ritonavir or Umifenovir or Chloroquine phosphate

Frame: 30 days]Fever to normal time (day)Pulmonary inflammation resolution time (High resolution Computed Tomography-HRCT) (day) [Time Frame: 30 days]Pulmonary inflammation resolution time (HRCT) (day) Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatment [Time Frame: 30 days]Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatment.

118. Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalized Patients With COVID-19 (ProPAC-COVID)(https://clinicaltrials.gov/ct2/show/NCT04322396) NCT04322396

DENMARK,Chronic Obstructive Pulmonary Disease Trial Network


Macrolide (Azithromycin)Anti-malaria Drug (Hydroxychloroquine)

Hydroxychloroquine + AzithromycinvsPlacebo

N/A Number of days alive and discharged from hospital within 14 days [Time Frame: 14 days]

>18y.o.

119. Safety and Efficacy of Hydroxychloroquine Associated With Azythromycin in SARS-Cov-2 Virus (Coalition-I) (https://clinicaltrials.gov/ct2/show/NCT04322123 ) NCT04322123

BRASIL,Hospital do Coracao, Hospital Israelita Albert Einstein, Hospital Sirio-Libanes



HydroxychloroquinevsHydroxychloroquine + AzithromycinvsStandard treatment

Hydroxychloroquine: 400 mg BID (PO) for 7 daysAzithromycin 500 mg OD (PO) for 7 days

Evaluation of the clinical status [Time Frame: 15 days after randomisation]Evaluation of the clinical status of patients on the 15th day after randomisation defined by the Ordinal Scale of 6 points. A) Alive at home B)In the hospital without oxygen C) In the hospital using oxygen D) In the hospital using high-flow nasal catheter or non-invasive ventilation E) In hospital, on mechanical ventilation F) Dead

≥18y.o.

120. Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)(https://clinicaltrials.gov/ct2/show/NCT04321278 ) NCT04321278

BRAZIL,Hospital do Coracao, Hospital Israelita Albert Einstein, Hospital Sirio-Libanes



Hydroxychloroquine + Azithromycin + Standard TreatmentvsHydroxychloroquine + Standard Treatment

Hydroxychloroquine: 400 mg BID (PO) for 7 daysAzithromycin 500 mg OD (PO) for 7 days

Evaluation of the clinical status [Time Frame: 15 days after randomisation]Evaluation of the clinical status of patients on the 15th day after randomisation defined by the Ordinal Scale of 6 points (score ranges from 1 to 6, with 6 being the worst score).

≥18y.o.

121. An Observational Case-control Study of the Use of Siltuximab in ARDS Patients Diagnosed With COVID-19 Infection (SISCO)(https://www.clinicaltrials.gov/ct2/show/NCT04323332 ) NCT04323332

ITALY,ASST - Papa Giovanni XXIII


Monoclonal Antibody/ Cytokine/ Cytokine-Antagonist (Siltuximab)

Cohort A: Siltiuximab in non ICU unitCohort B: Siltuximab in ICU unit

N/A Length of hospital stay (days) [Time Frame: First treatment date up to 3 months].

≥18y.o.

122. Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV

CHINA,Tangdu HospitalXi'an, Shaanxi

InterventionalSingle-centreSingle-arm

Monoclonal Antibody/Cytokine/ Cytokine Antagonist

Meplazumab Meplazumab 10mg IV once daily for 2 days

2019 nCoV nucleic acid detection [Time Frame: 14 days] Virological clearance rate using

18-75y.o.





https://clinicaltrials.gov/ct2/show/NCT04321278)%20NCT04321278

https://clinicaltrials.gov/ct2/show/NCT04321278)%20NCT04321278

https://clinicaltrials.gov/ct2/show/NCT04322123)NCT04322123








Pneumonia NCT04275245 Open-label (Meplazumab / anti-CD147)

Real-Time PCR in upper and/or lower respiratory tract samples at day 3, day 7 and day 14 respectively.

123. Tocilizumab in COVID-19 Pneumonia (https://clinicaltrials.gov/ct2/show/NCT04317092 , https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001110-38/IT/) NCT04317092, EudraCT Number: 2020-001110-38

ITALY, National Cancer Institute, Naples

InterventionalMulticentre Single-arm Open-label

Monoclonal Antibody/Cytokine/Cytokine Antagonist (Tocilizumab)

Tocilizumab Tocilizumab 8 mg/kg (max.800mg per dose), BID

One-month mortality rate [Time Frame: up to 1 month]1-month mortality is defined as the ratio of patients who will alive after 1month from study start out of those registered at baseline

All ages

124. Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 (https://www.clinicaltrials.gov/ct2/show/NCT04315298 ) NCT04315298

UNITED STATES, Regeneron Study Site New York,

Interventional Randomised Double-blind Placebo-controlled

Monoclonal Antibody/Cytokine/Cytokine Antagonist (Sarilumab)

Sarilumab high dose (IV) vs Sarilumab low dose (IV)vsPlacebo

N/A Percent change in C-reactive protein (CRP) levels [Time Frame: Day 4]Phase 2 OnlyTime to improvement (2 points) in clinical status assessment using the 7-point ordinal scale in patients with serum interleukin 6 levels greater than the upper limit of normal [Time Frame: Up to day 29 ]Phase 3 Only, 7-point Ordinal Scale: Death; Hospitalised, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO);Hospitalised, requiring non-invasive ventilation or high flow oxygen devices;Hospitalised, requiring supplemental oxygen;Hospitalised, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise)Hospitalised, not requiring supplemental oxygen - no longer requires ongoing medical careNot hospitalised

≥18y.o.

125. An adaptive phase 2/3, randomized, double-blind, placebo-controlled, study assessing efficacy and safety of sarilumab for hospitalized patients with COVID19(https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001162-12/FR/)EudraCT Number: 2020-001162-12

GLOBAL InterventionalRandomisedDouble-blinded Placebo-controlled

Monoclonal Antibody/Cytokine/Cytokine Antagonist (Sarilumab)

SarilumabvsPlacebo

Sarilumab: 200 mg

Phase 2: time to resolution of fever for at least 48 hours without antipyretics or until discharge, whichever is sooner Phase 3: The percentage of patients reporting each severity rating on the 7-point ordinal scaleTime point(s) of evaluation of this end point: Baseline to Day 29

≥18y.o.

126. Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure

DENMARKBispebjerg-Frederiksberg Hospital

Interventional RandomisedOpen-label

Monoclonal Antibody/Cytokine/Cytokine Antagonist

Tocilizumab (IV) + Standard Treatmentvs

Tocilizumab (IV): single dose 400mg

Time to independence from supplementary oxygen therapy [Time Frame: days from

≥18y.o






https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001110-38/IT/






(TOCIVID)(https://www.clinicaltrials.gov/ct2/show/NCT04322773 ) NCT04322773

Controlled (Sarilumab, Tocilizumab) Tocilizumab (SC) + Standard TreatmentvsSarilumab (SC) + Standard TreatmentvsStandard treatment

Tocilizumab (SC): 162 mg twiceSarilumab (SC): single dose 200 mg

enrolment up 28 days].

127. A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19) (http://www.chictr.org.cn/showprojen.aspx?proj=50251 ) ChiCTR2000030703

CHINA,Xiangya Hospital Third Xiangya Hospital


Monoclonal Antibody/Cytokine/Cytokine Antagonist (IL-17A Inhibitor) Antiviral

Ixekizumab and antiviral therapyvsAntiviral therapy

N/A Lung Computed TomographyMeasure time point of outcome: Days 7 and 14.

18-75y.o.

128. Eculizumab (Soliris) in Covid-19 Infected Patients (SOLID-C19) (https://clinicaltrials.gov/ct2/show/NCT04288713) NCT04288713

N/A Expanded AccessIndividual Patients Treatment IND/Protocol

Monoclonal Antibody/Cytokine/Cytokine Antagonist (Eculizumab)

N/A Eculizumab: 900mg once/week for 4 weeks, then 1200mg IV on 5th week, then 1200mg/14 days ongoing until at least one month after recovery. (IV)

Mortality, Time in the Intensive Care Unit, Time on a ventilator.

N/A

129. A multicenter, single arm, open label trial for the efficacy and safety of CMAB806 in the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-19) ChiCTR2000030196

CHINA,Central South Hospital of Wuhan University

Interventional MulticentreSingle-armOpen-labelControlled


Standard treatment +Tocilizumab

N/A The relive of Cytokine Release Syndrome.

≥18y.o.

130. Efficacy and safety of tocilizumab combined with adalimumab (Qletli) in severe and critical patients with novel coronavirus pneumonia (COVID-19) (http://www.chictr.org.cn/showprojen.aspx?proj=50693 ) ChiCTR2000030580

CHINA,Wuhan Leishenshan Hospital

Interventional Randomised Single-centreParallel-controlled

Monoclonal Antibody/Cytokine/Cytokine Antagonist (Tocilizumab, Adalimumab)

Standard treatment + Tocilizumab + AdalimumabvsStandard treatment

N/A Chest computerised tomography, nucleic acid detection of novel coronavirus, tumour necrosis factor-alpha, interleukin 6, interleukin 10.

18-80y.o.

131. Clinical Trial for Recombinant Human Interleukin-2 in the Treatment of Novel Coronavirus Pneumonia (COVID-19)ChiCTR2000030167



Monoclonal Antibody/Cytokine/Cytokine Antagonist (Human Recombinant IL-2)

Standard treatment + Low Dose Recombinant Human Interleukin-2vsStandard treatment + Placebo

Low Dose Recombinant Human Interleukin-2: 1 million IU every other day, 3 times/week for 2 weeks (IM)

CD8+ T cells numbers, CD4+ T cell numbers, Natural Killer cell numbers, Fatality rate, Clinical recovery time, Critical (severe or critical) conversion rate.

18-75y.o.

132. A clinical study for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel

CHINA,Shanghai Changzheng Hospital


Monoclonal Antibody/Cytokine/Cytokine Antagonist (Adalimumab)

Standard treatment + AdalimumabvsStandard treatment

N/A Time to Clinical Improvement (TTCI).

≥18y.o.

















coronavirus pneumonia (COVID-19) ChiCTR2000030089

133. Clinical comparative study of PD-1 mAb in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19) ChiCTR2000030028

CHINA,West China Hospital


Monoclonal Antibody/Cytokine/Cytokine Antagonist (anti-PD-1 Monoclonal Antibody)

Standard treatment + anti-PD-1 Monoclonal AntibodyvsStandard treatment only

N/A Neutrophil count, Lymphocyte count, Monocyte / macrophage count, Monocyte / macrophage function test, Natural Killer cell count, Dendritic Cell count, PD-1( immunosuppressive biomarker), PD-L1(immunosuppressive biomarker), CTLA4 (immunosuppressive biomarker), CD79, Interleukin 17 receptor, Blnk, T lymphocyte count, CD4+ T lymphocyte count, CD8+ T lymphocyte count, B lymphocyte count, Proportion of naive CD4+ T lymphocytes to CD4+ T lymphocytes, Proportion of memory CD4+ T lymphocyte to CD4+ T lymphocytes, Proportion of CD4+ T lymphocyte subsets to CD4+ T lymphocytes, Proportion of CD8+ CD28+ subsets to CD8 + T lymphocytes, Activation ratio of CD8+ T lymphocytes, Ratio of CD4+ T lymphocytes to CD8+ T lymphocytes.

≥18y.o

134. Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT( https://clinicaltrials.gov/ct2/ show/NCT04305106?term=NCT04305106&draw=2&rank=1 ) NCT04305106

CHINA, ITALYQilu Hospital, Renmin Hospital, MoriggiaPelasciniGravedona Hospital S.p.A, Wuhan University Jiangbei Union Hospital of Huazhong University, Shandong Provincial Chest Hospital

InterventionalRandomisedMulticentre Controlled

Monoclonal Antibody/Cytokine/Cytokine Antagonist (Bevacizumab)

Bevacizumab vsNo Intervention

Bevacizumab 500mg + 0.9% NaCl 100ml (IV)

The time from randomization to clinical improvement [Time Frame: No more than 28 days]The time from randomisation to an improvement of two points on a seven-category ordinal scale or live discharge from the hospital.

18-80y.o.

135. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19) ChiCTR2000029765

CHINA,The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital)

Interventional Multicentre Randomised Controlled


Standard treatment + TocilizumabvsStandard treatment only

N/A Neutrophil count, Lymphocyte count, Monocyte / macrophage count, Monocyte / macrophage function test, Natural Killer cell count, Dendritic Cell count, PD-1( immunosuppressive biomarker), PD-L1(immunosuppressive biomarker), CTLA4 (immunosuppressive biomarker), CD79, Interleukin 17 receptor, Blnk, T lymphocyte count, CD4+ T lymphocyte count, CD8+ T lymphocyte count, B lymphocyte count, Proportion of naive CD4+ T lymphocytes to CD4+ T lymphocytes, Proportion of

18-85y.o.












memory CD4+ T lymphocyte to CD4+ T lymphocytes, Proportion of CD4+ T lymphocyte subsets to CD4+ T lymphocytes, Proportion of CD8+ CD28+ subsets to CD8 + T lymphocytes, Activation ratio of CD8+ T lymphocytes, Ratio of CD4+ T lymphocytes to CD8+ T lymphocytes.

136. Cohort Multiple randomized controlled trials open-label of immune modulatory drugs and other treatments in COVID-19 patients (https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001246-18/FR/) EudraCT Number: 2020-001246-18

FRANCE,Hôpitaux de Paris

InterventionalRandomisedParallel-controlled Open-label

Monoclonal Antibody/Cytokine/Cytokine Antagonist (Sarilumab, Tocilizumab)

SarilumabvsStandard treatmentvsTocilizumabvsStandard treatment

Sarilumab: 200 mg injection (SC)Tocilizumab 20 ml (IV)

For the group 1 of patients not requiring Intensive Care Unit: Survival without needs of ventilator utilization (including Non invasive ventilation) at day 14. Events considered needing ventilator utilization (including Non Invasive Ventilation, NVI), or death. New don not resuscitate (DNR) order will be considered as an event at the date of the DNR.- Early end point : OMS progression scale < or = 5 at day 4, defined as follow (see protocol)For the group 2 of patients requiring ICU: -Cumulative incidence of successful tracheal extubation (defined as duration extubation> 48h) at day 14. Death or DNR order will be considered as a competing event.- Early end point : OMS progression scale >7 at day 4.

≥18y.o.

137. Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP) (https://clinicaltrials.gov/ct2/show/NCT04275414) NCT04275414

CHINA, Qilu Hospital of Shandong University


Monoclonal Antibody/Cytokine/Cytokine Antagonist (Bevacizumab)

Standard treatment + Bevacizumab

Bevacizumab: 500mg + normal saline (NS) 100ml, drip ≥90min (IV)

Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio [Time Frame: 24 hours]Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratioPartial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio [Time Frame: 72 hours]Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratioPartial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio [Time Frame: 7 days]Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio.

18-80y.o.






138. Favipiravir Combined With Tocilizumab in the Treatment of novel coronavirus pneumonia (COVID-19) - A Multicenter, Randomized, Controlled Trial (http://www.chictr.org.cn/showprojen.aspx?proj=51126 ) ChiCTR2000030894, NCT04310228

CHINAPeking University First Hospital,Tongji Hospital of Huazhong,Cancer Hospital Union Hospital Tongji Medical College Huazhong,West Hospital Union Hospital,Jinyintan Hospital of Wuhan,Huoshenshan Hospital of Wuhan,Wuhan Pulmonary Hospital,Zhongnan Hospital of Wuhan University,Anhui Medical University Affiliated First Hospital,Ezhou Central Hospital


Monoclonal Antibody/Cytokine/Cytokine Antagonist (Tocilizumab)Other antiviral (Favipiravir)

Favipiravir + tocilizumab vs Favipiravirvs Tocilizumab

Favipiravir: 1600mg BID on Day 1 (PO) then 600 mg BID on Day2- Day7 (PO)Tocilizumab: 4 ~ 8mg/kg (IV), recommended dose: 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours. Max. cumulative number: two, max. single dose < 800mg

Clinical cure rate [ Time Frame: 3 months ]Definition of clinical cure: The viral load of the respiratory specimen was negative for two consecutive times (the interval between the two tests was greater than or equal to one day), the lung image improved, and the body temperature returned to normal for more than 3 days, and the clinical manifestation improved.

18-65y.o.

139. Immunoregulatory Therapy for 2019-nCoV(https://clinicaltrials.gov/ct2/show/NCT04268537) NCT04268537

CHINA, Southeast University

Interventional RandomisedSingle – blindControlled

Monoclonal Antibody/Cytokine/Cytokine Antagonist (anti-PD-1 Monoclonal Antibody)Other agents(Thymosin a1)

Anti-PD-1 antibody + standard treatmentvsThymosin a1 + standard treatmentvsStandard treatment

Anti-PD-1 antibody, 200mg, (IV) statThymosin a1: 1.6 mg OD (SC) for 5 days

Lung injury score [Time Frame: 7 days]Proportion of lung injury score decreased 1 or more points.

≥18y.o.

140. A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia (https://clinicaltrials.gov/ct2/show/NCT04320615) NCT04320615

SWITZERLAND, Hoffmann-La Roche

InterventionalMulticentre RandomisedDouble-blindPlacebo-controlled


TocilizumabvsPlacebo + Standard Treatment

Tocilizumab: 8 mg/kg, max. dose 800 mg. (IV) Up to 1 additional dose if clinical symptoms worsen or no improvement

Clinical Status Assessed Using a 7-Category Ordinal Scale [Time Frame: Day 28].

≥18y.o.

141. Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19 (https://www.clinicaltrials.gov/ct2/show/NCT04306705 ) NCT04306705

CHINA, Tongji Hospital

RetrospectiveObservational Study

Monoclonal Antibody/Cytokine/Cytokine Antagonist (Tocilizumab)Adjuvant Device (CRRT)

Tocilizumab + Standard TreatmentvsContinuous Renal Replacement Therapy + Standard TreatmentvsStandard Treatment

Tocilizumab: 8 mg/kg (body weight) (IV)

Proportion of Participants With Normalization of Fever and Oxygen Saturation Through Day 14 [ Time Frame: First dose date up to 14 days ]This is a composite outcome measure. Criteria for fever normalization: Temperature < 36.6 °C armpit, < 37.2 °C oral sustained for at least 72 hours and criteria for oxygen normalization: peripheral capillary oxygen saturation (Sp02) > 94% sustained for at least 72 hours.

18-80y.o.

142. Tocilizumab for SARS-CoV2 ITALY, Interventional Monoclonal Tocilizumab Tocilizumab: Arrest in deterioration of ≥18y.o.









Severe Pneumonitis( https://clinicaltrials.gov/ct2/sho w/NCT04315480 ) NCT04315480

UniversitàPolitecnicadelle Marche

Single-arm Open-label

Antibody/Cytokine/Cytokine Antagonist (Tocilizumab)

single dose 8mg/Kg (IV)

pulmonary function [Time Frame: 7days]Rate of patients with no need in increase of fraction of inspired oxygen (FiO2) to maintain stable oxygen saturation and no need of intubationImproving in pulmonary function [Time Frame: 7 days]Rate of patients with change of oxygen saturation >3 percentage points or >10% or decrease in FiO2 need or reduction in pulmonary consolidations >30% at High resolution computed tomography scan.

143. A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19 ） ChiCTR2000030424, ChiCTR2000030487

CHINA,Henan Provincial People's Hospital

InterventionalSingle-centreSingle-arm

Nucleoside reverse transcriptase inhibitor(Azvudine)

Standard treatment +Azvudine

Azvudine (PO): Loading dose: 10 mg ODMaintenance: 5mg OD

Sputum/nasal swab/pharyngeal swab/lower respiratory tract secretions were used to detect the negative conversion rate of the new coronavirus nucleic acid (tested daily after two days starting the azvudine tablets) and the negative conversion time.

≥18y.o.

144. A single-arm, single-center clinical trial for Azivudine tablets in the treatment of adult novel coronavirus pneumonia (COVID-19)ChiCTR2000030041


InterventionalSingle-centre Single-arm


Standard treatment +Azvudine

N/A The novel coronavirus nucleic acid negative rate.

≥18 y.o.

145. A randomized, open-label, controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)ChiCTR2000029853

CHINA,People's Hospital of Guangshan County



Standard treatment +AzvudinevsStandard treatment

N/A Time and rate of temperature return to normal, Time and rate of improvement of respiratory symptoms and signs (lung rhones, cough, sputum, sore throat, etc.), Time and rate of improvement of diarrhoea, myalgia, fatigue and other symptoms, Time and rate of pulmonary imaging improvement, Time and rate of change to negative COVID-19 nucleic acid test, Time and rate of improvement of oxygenation measurement, Improvement time and rate of CD4 count, Rate of mild/moderate type to severe type, Rate of severe type to critical type, Length of hospitalisation, Mortality.

≥18 y.o.

146. Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) (COVID-19)(https://clinicaltrials.gov/ct2/show/NCT04322682) NCT04322682

CANADA,Montreal Heart Institute

InterventionalMulticentreRandomisedDouble-blindPlacebo-controlled

Other agents(Colchicine)

ColchicinevsPlacebo

Colchicine: 0.5 mg BID (PO) for the first 3 days, then OD for the last 27 days

Number of participants who die or require hospitalisation due to COVID-19 infection [Time Frame: 30 days post randomisation]The primary endpoint will be the

≥40y.o.














composite of death or the need for hospitalization due to COVID-19 infection in the first 30 days after randomization.

147. Colchicine Efficacy in COVID-19 Pneumonia (https://clinicaltrials.gov/ct2/show/NCT04322565) NCT04322565

ITALY,Universitaria di Parma


Other agents(Colchicine)

Standard treatment +ColchicinevsStandard treatment

Colchicine: 1mg (or 0.5 mg in chronic kidney disease) per day (PO)

Clinical improvement [Time Frame: Day 28]Time to clinical improvement: defined as time from randomization to an improvement of two points from the status at randomisation on a seven-category ordinary scaleHospital discharge [Time Frame: Day 28]Live discharge from the hospital (whatever comes first)

18-85y.o.

148. The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19 (https://clinicaltrials.gov/ct2/show/NCT04285190) NCT04285190

N/A InterventionalOpen-label RandomisedBlank-controlled

Other agents(T89)

Standard treatment + T89vsStandard treatment

T89: 30 tbs of T89 BID for 10 days (PO)

The time to oxygen saturation recovery to normal level (≥97%) [Time Frame: Day -1 to 10]From screening to the end of treatment, for all patients randomized, oxygen saturation will be assessed for 3 times daily, the time to oxygen saturation recovery to normal level (≥97%) will be calculated finally based on that record and compared between two groups.The proportion of patients with normal level of oxygen saturation (≥97%) [ Time Frame: Day -1 to 10 ]The proportion of patients with normal level of oxygen saturation (≥97%) after treatment will be calculated finally based on that record and compared between two groups

18-85y.o.

149. The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia (https://clinicaltrials.gov/ct2/show/NCT04273529) NCT04273529

CHINA,First Affiliated Hospital of Wenzhou Medical University, Second Affiliated Hospital of Wenzhou Medical University, Wenzhou Central Hospital

InterventionalMulticentreRandomisedDouble-blindPlacebo-controlled

Other agents(Thalidomide)

Thalidomide vsPlacebo

Thalidomide: 100mg OD for 14 days (PO)

Time to Clinical Recovery (TTCR) [Time Frame: up to 28 days]TTCR is defined as the time (in hours) from initiation of study treatment (active or placebo) until normalisation of fever, respiratory rate, and oxygen saturation, and alleviation of cough, sustained for at least 72 hours. Normalisation and alleviation criteria: Fever - ≤36.6°C or -axilla, ≤37.2 °C oral or ≤37.8°C rectal or tympanic, Respiratory rate - ≤24/minute on room air, Oxygen saturation - >94% on room air, Cough - mild or absent on a patient reported

≥18y.o.





https://clinicaltrials.gov/ct2/show/NCT04322565?cond=NCT04322565&draw=2&rank=1

https://clinicaltrials.gov/ct2/show/NCT04322565?cond=NCT04322565&draw=2&rank=1

scale of severe, moderate, mild, absent.

150. A randomized, double-blind, placebo-controlled trial for evaluation of the efficacy and safety of bismuth potassium citrate capsules in the treatment of patients with novel coronavirus pneumonia (COVID-19).ChiCTR200030398



Other agents(Bismuth potassium)

Standard treatment + Bismuth potassium citrate capsulesvsStandard treatment +Placebo

Bismuth potassium citrate: 2 capsules x 1 BID (PO)

Pharynx swabs, lower respiratory tract samples (sputum/endotracheal aspiration/alveolar lavage), and anal swabs Reverse transcription polymerase chain reaction (RT-PCR) of novel coronavirus nucleic acid negative conversion rate.Measure time point of outcome: Day 15.

18-75y.o.

151. Clinical application of inhaled acetylcysteine solution in the treatment of novel coronavirus pneumonia (COVID-19) ChiCTR2000030328

CHINA,Union Hospital, Tongji Medical College, Huazhong University of Science & Technology

Interventional RandomisedSingle-centrePlacebo-controlled

Other agents(Acetylcysteine)

Inhaled AcetylcysteinevsPlacebo

N/A Lung Computed Tomography (CT) after 3 days, Lung CT after 7 days, oxygenation parameters: SpO2, Partial arterial oxygen pressure (PaO2), Ratio of partial pressure arterial oxygen and fraction of inspired oxygen, hospital stay, Novel coronavirus nucleic acid detection, Recurrence rate.

≥18y.o.

152. A multi-center study on the efficacy and safety of suramin sodium in adult patients with novel coronavirus pneumonia (COVID-19) ChiCTR2000030029

CHINA,The First Affiliated Hospital of Zhejiang University School of Medicine

Interventional MulticentreSingle-arm

Other agents(Suramin)

Patients will receive Suramin Sodium (IV)

N/A Clinical cure rate, Incidence of mechanical ventilation by day 28, All-cause mortality by day28, incidence of Intensive Care Unit admission by day28.

18-75y.o.

153. Basic and clinical study of inhalation of inactivated mycobacterium vaccine in the treatment of Novel coronavirus pneumonia (COVID-19) ChiCTR2000030016

CHINA,The fourth people's hospital of Nanning, Guangxi

Interventional RandomisedSingle-centrePlacebo-controlled

Other agents(Inactivated Mycobacterium Vaccine)

Standard treatment + Inactivated Mycobacterium Vaccine inhalationvsStandard treatment + Placebo

N/A Viral negative-transforming time, 30-day cause-specific mortality, 30-day cause-adverse events, 30-day all-cause mortality, Co-infections, Time from severe and critical patients to clinical improvement, Others (liver function, kidney function, myocardial enzyme).

18-80y.o.

154. Multicenter randomized controlled trial for rhG-CSF in the treatment of novel coronavirus pneumonia (COVID-19) ChiCTR2000030007

CHINA,The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Eighth People's Hospital, Union Hospital, Wuhan Hankou Hospital


Other agents(rhG-CSF)

Standard treatment + rhG-CSFvsStandard treatment

rhG-CSF: 5μg/kg (IV)

Clinical symptoms, blood routine, the viral load of 2019-nCOV of throat swab, TBNK cell subsets, TH1/TH2 Cytokine, Chest Computed Tomography.

15-80y.o.

155. The Impact of Camostat Mesilate on COVID-19 Infection (https://clinicaltrials.gov/ct2/show/NCT04321096 ) NCT04321096

DENMARK, University of Aarhus

InterventionalRandomisedPlacebo-controlled

Other agents(TMPRSS2 inhibitor Camostat Mesilate)

Camostat MesilatevsPlacebo

Camostat Mesilate : 200 mg TID for 5 days (PO)

Cohort 1: Days to clinical improvement from study enrolment [Time Frame: 30 days]Clinical improvement defined as live hospital discharge OR a 2 point improvement (from time of enrolment) in disease severity rating on the 7-point ordinal scaleCohort 2: Days to clinical

18-110y.o.


















improvement from study enrolment [Time Frame: 30 days]Days to clinical improvement from study enrolment defined no fever for at least 48 hrs AND improvement in other symptoms (e.g. cough, expectoration, myalgia, fatigue, or head ache)

156. A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2 (https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001243-15/BE/ ) EudraCT Number: 2020-001243-15

BELGIUM,UZLeuven

InterventionalRandomised Open-labelParallel-controlled

Other agents(Itraconazole)

ItraconazolevsStandard Treatment

N/A Clinical status of subject at day 15 (on a 7-point ordinal scale):1. Not hospitalised, no limitations on activities2. Not hospitalised, limitation on activities;3. Hospitalised, not requiring supplemental oxygen;4. Hospitalised, requiring supplemental oxygen;5. Hospitalised, on non-invasive ventilation or high flow oxygen devices;6. Hospitalised, on invasive mechanical ventilation or ECMO;7. Death.Time point(s) of evaluation of this end point: Day 15

≥18y.o.

157. Immunomodulatory Therapy for Severe Novel Coronavirus Pneumonia (COVID-19)ChiCTR2000029806


InterventionalRandomisedControlled

Other agents(Thymosin a1)Monoclonal Antibody/Cytokine/ Cytokine Antagonist (anti-PD-1 Monoclonal Antibody)

Anti-PD-1 antibody + standard treatmentvsThymosin a1 + standard treatmentvsStandard treatment

Camrelizumab (PD-1): 200mg single doseThymosin a: 1.6mg sc daily for 5 days

Proportion of patients with a lung injury score reduction of 1-point or more 7 days after randomisation.

≥18y.o.

158. A prospective, randomized, open-label, interventional study to investigate the efficacy of sargramostim (Leukine®) in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure. (https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001254-22/BE) EudraCT Number: 2020-001254-22

BELGIUM,University Hospital Ghent

Interventional RandomisedOpen-label Controlled

Other agents (Sargramostim: GM-CSF)

GM-CSFvsPlacebo

GM-CSF: 250 mcg OD during 5 days (INH)

Oxygenation measurementMeasurement after 5 DAYS of inhaled (and intravenous) treatment through assessment of pretreatment (day 0) and post-treatment (day 5) ratio of PaO2/FiO2 and through measurement of the P(A-a)O2 gradient, which can easily be performed in the setting of clinical observation of patients admitted to the COVID -19 ward or ICU COVID-19 unit. Preferentially, this measurement should be done in the upright position, while breathing room air for a minimum of 3 minutes.. If this is impossible due to need for supplemental oxygen, FiO2 and oxygen supplementation method should be recorded in

18-80y.o.

https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001254-22/BE






https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001243-15/BE/



patient record, so that A-a gradient can be normalized for age expected normal A-a gradient while on supplemental oxygen use.During the 5 day treatment period, we will perform daily measurements of oxygen saturation (pulse oximetry) in relation to FiO2, and the slope of alterations in this parameters could also be an indicator that our hypothesis is correct.If the patient leaves hospital prior to the day 6 analysis point, oxygenation at day of discharge will be used as value for measuring primary endpoint.

159. Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) (https://clinicaltrials.gov/ct2/show/NCT04273763) NCT04273763

CHINA,Second Affiliated Hospital of Wenzhou Medical University


Other antiviral(Umifenovir, Favipiravir )InterferonDietary and Supportive Measures(Bromhexine Hydrochloride)

Bromhexine + Recombinant Human Interferon α2b Spray + Umifenovir + Favipiravir vsRecombinant Human Interferon α2b Spray + Umifenovir

N/A Time to clinical recovery after treatment [Time Frame: within 14 days from the start of medication]Defined as random to fever, respiratory rate return to normal and cough remission over 48 hours.Rate of aggravation [Time Frame: within 14 days from the start of medication]Aggravation was defined as(one of them): respiratory distress, Respiratory Rate ≥ 30 times / min; SpO2 ≤ 93% in resting state; arterial partial pressure of oxygen (PaO2) /concentration of oxygen (FiO2) ≤ 300mmHg.

18-80y.o.

160. The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19 (https://clinicaltrials.gov/ct2/show/NCT04273581) NCT04273581

CHINA,First Affiliated Hospital of Wenzhou Medical University,Second Affiliated Hospital of Wenzhou Medical University,Wenzhou Central Hospital


Other antiviral(Umifenovir)InterferonOther Agents(Thalidomide)Corticosteroids

Interferon alpha + Methylprednisolone + Umifenovir + ThalidomidevsInterferon alpha + Methylprednisolone + Umifenovir + Placebo

Interferon alpha: 5 million U or equivalent dose BID for 7 days (NEB) Umifenovir: 200mg TID for 7 days (PO)Methylprednisolone: 40mg BID for 5 days (PO)Thalidomide: 100mg/d OD for 14 days (PO)

Time to Clinical Improvement (TTCI) [Time Frame: up to 28 days]TTCI is defined as the time (in days) from initiation of study treatment (active or placebo) until a decline of two categories from admission status on a six-category ordinal scale of clinical status which ranges from 1 (discharged) to 6 (death). Six-category ordinal scale: 6. Death; 5. ICU, requiring ECMO and/or IMV; 4. ICU/hospitalisation, requiring NIV/ HFNC therapy; 3. Hospitalisation, requiring supplemental oxygen (but not NIV/ HFNC); 2. Hospitalisation, not requiring supplemental oxygen; 1. Hospital discharge.

≥18y.o.





Abbreviation: IMV, invasive mechanical ventilation; NIV, non-invasive mechanical ventilation; HFNC, High-flow nasal cannula.

161. Randomized controlled trial for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir/ritonavirChiCTR2000030113

CHINA,The Third People's Hospital of Shenzhen


Other antiviral(Favipiravir)Protease Inhibitor(Lopinavir/ritonavir)

FavipiravirvsLopinavir/ritonavir

N/A Blood routine tests, Liver function examination, Renal function examination, Blood gas analysis, Chest Computed Tomography examination.

16-75y.o.

162. A randomized, open-label, controlled trial for the efficacy and safety of Farpiravir Tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19) ChiCTR2000029996

CHINA,Beijing Chaoyang Hospital, Capital Medical University


Other antiviral(Favipiravir)

Low-dose FavipiravirvsMiddle-dose FavipiravirvsHigh-dose Favipiravir

Low dose Favipiravir: 1600mg BID at Day 1 Middle dose Favipiravir: 1800mg BID at Day 1High dose Favipiravir:2400mg BID at Day 1Then 200mg BID for 9 days (PO)

Time to Clinical RecoveryMeasure time point of outcome: Observation until discharge or turn to severeMeasure method: Duration of at least 72 hours from the start of study treatment to normal body temperature (underarm temperature <= 36.9 degrees C) and cough relief (evaluated by the cough symptom score scale) Use antipyretics, and in hours).

≥18y.o.

163. A randomized, open-label, blank-controlled, multicenter trial for Polyinosinic-Polycytidylic Acid Injection in the treatment of novel coronavirus pneumonia (COVID-19) ChiCTR2000029776

CHINA,The First Affiliated of Wenzhou Medical University, The Second Affiliated of Wenzhou Medical University

Interventional RandomisedControlledMulticentre

Other antiviral(Polyinosinic-Polycytidylic Acid)

Standard treatment + Polyinosinic-Polycytidylic Acid InjectionvsStandard treatment only

N/A Time to Clinical recovery. ≥18y.o.

164. Clinical study for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) ChiCTR2000029600

CHINA,The Third People's Hospital of Shenzhen


Other antiviral(Favipiravir)InterferonProtease Inhibitor(Lopinavir/ritonavir)

Interferon alpha atomizationvsInterferon alpha atomization + FavipiravirvsInterferon alpha atomization + Lopinavir/ritonavir

N/A Declining speed of Novel Coronavirus by Polymerase chain reaction (PCR), negative Time of Novel Coronavirus by PCR, incidence rate of chest imaging, incidence rate of liver enzymes, and incidence rate of kidney damage.

16-75y.o.

165. Clinical study of arbidol hydrochloride tablets in the treatment of novel coronavirus pneumonia (COVID-19)Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus (https://clinicaltrials.gov/ct2/show/NCT04260594) NCT04260594, ChiCTR2000029621

CHINA,Ruijin Hospital

Interventional RandomisedMulticentre Open-labelControlled

Other antiviral (Umifenovir)

Standard treatment + Arbidol (Umifenovir)vsStandard treatment only

Umifenovir: 2tbs TID for 14-20 days (PO)

Virus negative conversion rate in the first week [Time Frame: first week].

18-75y.o.

166. Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With

N/A Interventional RandomisedOpen-label

Other antiviral(Remdesivir)

Standard treatment + Remdesivir for 5 daysvs

Remdesivir: 200 mg on Day 1 followed 100 mg

The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14 [Time

≥18y.o.


















Severe Coronavirus Disease (COVID-19) (https://clinicaltrials.gov/ct2/show/NCT04292899, https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000841-15/DE/ ) NCT04292899, EudraCT Number: 2020-000841-15

Standard therapy + Remdesivir for 10 days

for another 4 or 9 days (IV)

Frame: Day 14]The odds ratio represents the odds of improvement in the ordinal scale between the treatment groups. The ordinal scale is an assessment of the clinical status at a given day. Each day, the worst score from the previous day will be recorded. The scale is as follows: 1. Death 2. Hospitalised, on invasive mechanical ventilation or Extracorporeal Membrane Oxygenation (ECMO) 3. Hospitalised, on non-invasive ventilation or high flow oxygen devices 4. Hospitalised, requiring low flow supplemental oxygen 5. Hospitalised, not requiring supplemental oxygen - requiring ongoing medical care (coronavirus (COVID-19) related or otherwise) 6. Hospitalised, not requiring supplemental oxygen - no longer required ongoing medical care (other than per protocol Remdesivir administration 7. Not hospitalised.

167. Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment (https://clinicaltrials.gov/ct2/show/NCT04292730, https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000842-32/DE/ ) NCT04292730, EudraCT Number: 2020-000842-32

N/A Interventional RandomisedOpen-labelControlled


Standard therapy + Remdesivir for 5 daysvsStandard therapy + Remdesivir for 10 days vsStandard treatment

Remdesivir: 200 mg on Day 1 followed 100 mg for another 4 or 9 days (IV)

The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11 [Time Frame: Day 11]The odds ratio represents the odds of improvement in the ordinal scale between the treatment groups. The ordinal scale is an assessment of the clinical status at a given day. Each day, the worst score from the previous day will be recorded. The scale is as follows: 1. Death 2. Hospitalized, on invasive mechanical ventilation or Extracorporeal Membrane Oxygenation (ECMO) 3. Hospitalized, on non-invasive ventilation or high flow oxygen devices 4. Hospitalised, requiring low flow supplemental oxygen 5. Hospitalised, not requiring supplemental oxygen - requiring ongoing medical care (coronavirus (COVID-19) related or otherwise) 6. Hospitalised, not requiring supplemental oxygen - no longer

≥18y.o.











required ongoing medical care (other than per protocol Remdesivir administration 7. Not hospitalised.

168. Adaptive COVID-19 Treatment Trial (https://clinicaltrials.gov/ct2/show/NCT04280705, https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001052-18/DK/ ) NCT04280705, EudraCT Number: 2020-001052

GLOBAL,50 sites

Interventional RandomisedMulticentreDouble-blindPlacebo-controlled


Remdesivir for 5 daysvsPlacebo

Remdesivir: 200 mg on Day 1 followed 100 mg for another 4 days

Time to recovery [Time Frame: Day 1 through Day 29]Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the ordinal scale: 1) Hospitalised, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalised, limitation on activities and/or requiring home oxygen; 3) Not hospitalised, no limitations on activities.

18-99y.o.

169. A pilot study for Integrated Chinese and Western Medicine in the treatment of non-critical novel coronavirus pneumonia (COVID-19) ChiCTR2000029993

CHINA,The First Affiliated Hospital of Guangzhou Medical University, Xianning Central Hospital, First People's Hospital of Yunnan Province, Wuhan Sixth Hospital

Interventional MulticentreRandomisedOpen-labelControlled

Other antiviral(Umifenovir)Traditional Chinese Medicine

Standard treatment + Arbidol Hydrochloride + Liushen CapsulevsStandard treatment

N/A Main symptom relief timeMeasure method: Temperature/oxygen saturation/respiratory rate.

≥18y.o.

170. A randomized, open-controlled trial for farpiravir tablets in the treatment of novel coronavirus pneumonia (COVID-19)ChiCTR2000030254



Other antiviral(Favipiravir, Umifenovir)

FavipiravirvsUmifenovir

N/A Clinical recovery rate of day 7. 18-75y.o.

171. A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Mild and Moderate 2019-nCoV Respiratory Disease. (https://clinicaltrials.gov/ct2/show/NCT04252664) NCT04252664

CHINA,China-Japan Friendship Hospital

InterventionalRandomisedDouble-blindPlacebo-controlled Multicentre


Remdesivir vsPlacebo

Remdesivir: 200 mg loading dose on Day 1, then 100 mg OD (IV) for 9 days

Time to Clinical Recovery (TTCR) [Time Frame: up to 28 days]TTCR is defined as the time (in hours) from initiation of study treatment (active or placebo) until normalisation of fever, respiratory rate, and oxygen saturation, and alleviation of cough, sustained for at least 72 hours, or live hospital discharge, whichever comes first.Normalisation and alleviation criteria: Fever - <37°C, Respiratory rate - ≤24/minute on room air, Oxygen saturation - >94% on room air, Cough - mild or absent on a patient reported scale of severe, moderate, mild, absent.

≥18y.o.

172. A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir

CHINA,China-Japan Friendship Hospital

InterventionalRandomisedDouble-blindPlacebo-controlled


Remdesivir vsPlacebo

Remdesivir: 200 mg loading dose on Day 1, then 100 mg OD (IV)

Time to Clinical Improvement (TTCI) [Censored at Day 28] [ Time Frame: up to 28 days ]The primary endpoint is time to

≥18y.o.









https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001052-18/DK/





in Hospitalized Adult Patients With Severe 2019-nCoVRespiratory Disease. (https://clinicaltrials.gov/ct2/show/NCT04257656) NCT04257656

Multicentre for 9 days clinical improvement (censored at Day 28), defined as the time (in days) from randomization of study treatment (remdesivir or placebo) until a decline of two categories on a six-category ordinal scale of clinical status (1 ꞊ discharged; 6 ꞊ death) or live discharge from hospital.Six-category ordinal scale: 6. Death; 5. ICU, requiring ECMO and/or IMV; 4. ICU/hospitalization, requiring NIV/ HFNC therapy; 3. Hospitalization, requiring supplemental oxygen (but not NIV/ HFNC); 2. Hospitalization, not requiring supplemental oxygen; 1. Hospital discharge or meet discharge criteria (discharge criteria are defined as clinical recovery, i.e. fever, respiratory rate, oxygen saturation return to normal, and cough relief). Abbreviation: IMV, invasive mechanical ventilation; NIV, non-invasive mechanical ventilation; HFNC, High-flow nasal cannula.

173. A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV PneumoniaNCT04254874

CHINA,Hubei, Department and Institute of Infectious Diseases

InterventionalRandomisedControlled Open-label

Other Antiviral (Umifenovir)Interferon

Arbidol hydrochloridevsArbidol hydrochloride + Interferon atomization

Umifenovir: 0.2g TID for 14 daysInterferon (PegIFNα2β) atomization: 45ug add to sterile water 2ml, BID for 14 days

Rate of disease remission [Time Frame: two weeks]A: For mild patients : fever, cough and other symptoms relieved with improved lung Computed Tomography (CT); B:For severe patients: fever, cough and other symptoms relieved with improved lung CT, SPO2> 93% or Ratio of arterial oxygen partial pressure to fractional inspired oxygen > 300mmHg (1mmHg=0.133Kpa)Time for lung recovery [Time Frame: two weeks]Compare the average time of lung imaging recovery after 2 weeks of treatment in each group.

≥18y.o.

174. Preliminary evaluation of the safety and efficacy of oral LL-37 antiviral peptide (CAS001) in the treatment of novel coronavirus pneumonia (COVID-19) (http://www.chictr.org.cn/showprojen.aspx?proj=51059)

CHINA,PLA general hospital, Beijing Hankou hospital in Wuhan

InterventionalNon-randomised

Other antiviral (Antiviral peptide LL-37)

Oral LL-37 antiviral peptide (CAS001)

N/A Nuclear acid test of faeces, nuclear acid test of the upper respiratory tract, IgM, IgG, CT test of lung, glutamic oxalacetic transaminase, glutamic-pyruvic transaminase, total bilirubin, direct bilirubin, urea nitrogen, lactic dehydrogenase, creatinine,

≥14y.o.








ChiCTR2000030939 lymphocyte, C-reactive protein, procalcitoninm erythrocyte sedimentation rate.

175. A Randomized Controlled Trial for Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia (COVID-19) (http://www.chictr.org.cn/showprojen.aspx?proj=51329 ) ChiCTR2000030987, NCT04319900

CHINA, Beijing Chao-yang Hospital


Other antiviral (Favipiravir)Anti-malaria drug (Chloroquine)

Favipiravir + Chloroquine phosphatevsFavipiravir vsPlacebo

N/A Time of Improvement or recovery of respiratory symptoms [Time Frame: 10 days during the intervention period]Time of improvement or recovery of respiratory symptomsNumber of days virus nucleic acid shedding [Time Frame: 10 days during the intervention period]Number of days from positive to negative for test of swab or sputum virus nucleic acidFrequency of Improvement or recovery of respiratory symptoms [Time Frame: 10 days during the intervention period]Frequency of improvement or recovery of respiratory symptoms

18-75y.o.

176. Intermediate-Size Patient Population Expanded Access Treatment Protocol for Coronavirus Disease 2019 (COVID-19) Remdesivir (RDV; GS-5734™) (https://www.clinicaltrials.gov/ct2/show/NCT04302766?term=NCT04302766&draw=2&rank=1 ) NCT04302766

UNITED STATES,U.S. Army Medical Research and Development Command

Expanded access Treatment IND/Protocol

Other antiviral (Remdesivir)

Remdesivir N/A None(Expanded Access Status)

All ages

177. The efficacy and safety of Triazavirin for 2019 novel coronary pneumonia (COVID-19): a multicenter, randomized, double blinded, placebo-controlled trial ChiCTR2000030001

CHINA,Health commission of Heilongjiang province

InterventionalMulticenterRandomisedDouble-blindPlacebo-controlled

Other antivirals(Triazavirin)

Triazavirin + standard treatmentvsStandard treatment

N/A Time to Clinical recovery. ≥18y.o.

178. Clinical study for combination of anti-viral drugs and type I interferon and inflammation inhibitor TFF2 in the treatment of novel coronavirus pneumonia (COVID-19) ChiCTR2000030262



Other Biological Agents(Inflammation inhibitor - Trefoil Family Factor 2 peptide-TFF2)Interferon

IFN-κ + TFF2 once for 2 daysvsIFN-κ + TFF2 once for 1 dayvsStandard treatment

N/A Viral load, clinical features, inflammation, pulmonary imaging, in-hospital days.

18-70y.o.

179. Clinical study of novel NLRP Inflammasome inhibitor (Tranilast) in the treatment of novel coronavirus pneumonia (COVID-19)ChiCTR2000030002

CHINA,The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital)

Interventional RandomisedDouble-blindControlled

Other Biological Agents(NLRP Inflammasome inhibitor -Tranilast)

Standard treatment + TranilastvsStandard treatment

N/A Cure rate. 18-85y.o.

180. Efficacy and safety of aerosol inhalation of vMIP in the treatment of novel coronavirus pneumonia (COVID-19): a single arm clinical


Interventional Single-armMulticentre Open-label

Other Biological Agents(vMIP)

Standard treatment + vMIP atomized inhalation

N/A 2019-nCoV nucleic acid turning negative time (from respiratory secretion), or the time to release isolation.

≥18y.o.

















trial ChiCTR2000029636181. Clinical study for the remedy of

M1 macrophages target in the treatment of novel coronavirus pneumonia (COVID-19)ChiCTR2000029431

CHINA,Affiliated Zhongshan Hospital of Dalian University, Zhongnan Hospital of Wuhan University

Interventional RandomisedMulticentre Controlled

Other Biological Agents(M1 (type I macrophage) inhibition therapy)

Standard treatment + Ankylosaurus+M1 suppression therapyvsStandard treatment + AnkylosaurusvsStandard treatment only

N/A Computed Tomography of lung, Computed Tomography and Magnetic resonance imaging of hip.

≥18y.o.

182. Fingolimod in COVID-19 (https://clinicaltrials.gov/ct2/show/NCT04280588) NCT04280588

CHINA,First Affiliated Hospital of Fujian Medical University

Interventional Non-randomisedOpen-label Controlled

Other Biological Agents(Fingolimod)

FingolimodvsNo intervention

Fingolimod: 0.5mg OD for 3 days (PO)

The change of pneumonia severity on X-ray images [Time Frame: 5 day after fingolimod treatment]The lesion change on X-ray images from day 5 to baseline.

18-85y.o.

183. Escin in Patients With Covid-19 Infection (add-on-COV2)(https://www.clinicaltrials.gov/ct2/show/NCT04322344 ) NCT04322344

ITALY,University of Catanzaro

InterventionalNon-randomised Parallel-controlledDouble-blind

Other biological agents (Escin)

Escin (IV) + standard treatmentvsEscin (PO) + standard treatmentvsStandard teatment

Escin: 40 mg TID (PO) for 12 days or 20mg per day (IV) for 12 days

Mortality rate [ Time Frame: up to 30 days ]All cause mortality- Clinical status evaluated in agreement with guidelines [ Time Frame: up to 30 days ]Mild type: no No symptoms, Radiological examination: no pneumonia; possible mild increase in C-reactive protein 2, Moderate type: fever, cough, or other respiratory symptoms. Radiological examination: pneumonia, SpO2＞93% without oxygen inhalation ; increase in C reactive protein, 3: severe type: a. Rate ≥30bpm；b. Pulse Oxygen Saturation (SpO2)≤93% without oxygen inhalation，c. PaO2/FiO2(fraction of inspired oxygen )≤300mmHg ；4. Critically type: match any of the follow: a. need mechanical ventilation; b. shock; c. (multiple organ dysfunction syndrome) MODS.

18-75y.o.

184. A randomized, open label, parallel controlled trial for evaluating the efficacy of recombinant cytokine gene-derived protein injection in eliminating novel coronavirus in patients with novel coronavirus pneumonia (COVID-19)ChiCTR2000029496

CHINA,The First Hospital of Changsha; The Second Xiangya Hospital of Central South University, The Fourth People's Hospital of Yiyang, The Second People's Hospital of Changde, The First People's Hospital of Yueyang, The First People's Hospital of Huaihua.

Interventional RandomisedMulticentre Controlled

Other Biological Agents (Recombinant cytokine gene-derived protein - Novaferon)Protease Inhibitor(Lopinavir/ritonavir)

Standard treatment + NovaferonvsStandard treatment + Lopinavir/ritonavirvsStandard treatment + Novaferon + Lopinavir/ritonavir

Novaferon: 20μg BID for 7-14 days.Lopinavir/ritonavir BID (PO) for 7-14 days.

Novel coronavirus nucleic acid clearance rateMeasure time point of outcome: on day 6 after treatmentMeasure method: Polymerase chain reaction (PCR).

18-70y.o.

185. CD24Fc as a Non-antiviral UNITED STATES, Interventional Other Biological Agents CD24Fc + Standard Single dose Improvement of COVID-19 ≥18y.o.












Immunomodulator in COVID-19 Treatment (https://www.clinicaltrials.gov/ct2/show/NCT04317040 ) NCT04317040

Institute of Human Virology, University of Maryland Baltimore

Multicentre RandomisedDouble-blindPlacebo-controlled

(Recombinant fusion protein - CD24Fc)

treatmentvs Placebo + Standard treatment

CD24Fc, 480mg, diluted to 100ml with normal saline

disease status [Time Frame: 14 days]Time to improve in clinical status: the time (days) required from the start of treatment to the improvement of clinical status "severe" to "moderate/mild"; or improvement from "scale 3 or 4" to "scale 5 or higher" based on NIAID ordinal scales.Disease progression of COVID-19 [Time Frame: 28 days]Time for disease progression from NIAID scale 3 or 4 to scale 2 or 1, and patients need to be on invasive mechanical ventilation, or ESMO, or death.

186. Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress (https://www.clinicaltrials.gov/ct2/show/NCT04311697 ) NCT04311697

UNITED STATES, ISRAEL NYU Langone Medical Center New YorkRambam Health Care Campus

InterventionalRandomised MulticentrePlacebo-controlled

Other Biological Agents (Vasoactive intestinal polypeptide (VIP) Aviptadil)

Aviptadil in escalating doses + maximal intensive care vsPlacebo + maximal intensive care

Aviptadil in escalating doses of 50 pmol, 100 pmol, 150 pmol/kg/hr (IV)

Mortality [Time Frame: 5 Days with follow up through 30 days]Mortality- PaO2:FiO2 ratio [Time Frame: 5 Days with follow up through the end of telemetry monitoring]Index of Respiratory Distress

18-100y.o.

187. Multicenter study for the treatment of Dipyridamole with novel coronavirus pneumonia (COVID-19)ChiCTR2000030055

CHINA,The First Affiliated Hospital of Guangzhou Medical University, Wuhan University People's Hospital, Union Hospital, Wuhan Huangpi District Hospital of traditional Chinese Medicine, Dawu County People's Hospital, The First Affiliated Hospital of Wenzhou Medical University, Zhuhai People's Hospital


Phosphodiesterase Inhibitor(Dipyridamole)

Standard treatment + DipyridamolevsStandard treatment

N/A Complete blood count, CRP, blood coagulation, D-dimer, virological examination of pharyngeal swab, pulmonary imaging.

18-70y.o.

188. A Pilot Study of Sildenafil in COVID-19 (https://www.clinicaltrials.gov/ct2/show/NCT04304313) NCT04304313

CHINA, Tongji Hospital

InterventionalSingle-arm Open-label

Phosphodiesterase-Inhibitor (Sildenafil)

Sildenafil citrate tablets Sildenafil: 0.1g OD for 14 days (PO)

Rate of disease remission [Time Frame: 14 days]fever, cough and other symptoms relieved with improved lung Computed Tomography; SPO2>93% or Ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2) >300mmHg without oxygen inhalation.Rate of entering the critical stage [Time Frame: 14 days]Comply with any of the followings: Respiratory failure occurs and requires mechanical ventilation; Shock; Patients

≥18y.o.










combined with other organ failure need ICU monitoring and treatment.Time of entering the critical stage [Time Frame: 14 days]Comply with any of the followings: Respiratory failure occurs and requires mechanical ventilation; Shock; Patients combined with other organ failure need ICU monitoring and treatment.

189. Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection (https://clinicaltrials.gov/ct2/show/NCT04251871) NCT04251871

CHINAThe Fifth Medical Center, General Hospital of PLA Beijing


Protease inhibitor(Lopinavir/ritonavir)InterferonTraditional Chinese Medicine

Conventional medicines vs Conventional medicines + Traditional Chinese Medicines (TCMs) granules

Interferon alpha (INH) + Lopinavir/ritonavir: 400/100mg BID (PO) for 14 daysTCMs granules: one bag BID (PO) for 14 days

The incidents of acute respiratory distress syndrome (ARDS) development [Time Frame: 14 days]The incidence rate of acute respiratory distress syndrome (ARDS) development.

14-80y.o.

190. Study of Pinavir / Ritonavir Tablets (Trade Name: Kelizhi) Combined with Xiyanping Injection for Novel Coronavirus Pneumonia (COVID-19) ChiCTR2000030218

CHINA,Fifth People's Hospital of Ganzhou


Protease Inhibitor(Lopinavir/ritonavir)Traditional Chinese Medicine

Standard treatment + Lopinavir/ritonavir + Xiyanping injection (ordinary and severe groups)vsLopinavir/ritonavir only

N/A Clinical recovery time, Pneumonia Severity Index (PSI) Score.

≥18y.o.

191. Clinical study for Lopinavir and Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) ChiCTR2000030187

CHINA,Jingzhou First People's Hospital


Protease Inhibitor(Lopinavir/ritonavir)

Standard treatment + Lopinavir/ritonavirvsStandard treatment only

N/A Endotracheal intubation rateMeasure time point of outcome: Within 14 daysMortalityMeasure time point of outcome: Within 30 daysRatio of virus nucleic acid detection to negativeMeasure time point of outcome: 14 day, Measure method: Immunofluorescence.

18-80y.o.

192. A multicenter, randomized, open-label, positive-controlled trial for the efficacy and safety of recombinant cytokine gene-derived protein injection combined with abidole, lopinavir/litonavir in the treatment of novel coronavirus pneumonia (COVID-19) patientsChiCTR2000029573

CHINA,The First Affiliated Hospital of Medical College of Zhejiang University

Interventional Multicentre RandomisedOpen-labelPositive-controlled

Protease Inhibitor(Lopinavir/ritonavir)Other antiviral(Umifenovir )Other Biological Agents(Recombinant cytokine gene-derived protein-Novaferon)

Arbidol (Umifenovir )vsRecombinant cytokine gene-derived protein (Novaferon) + Arbidol (Umifenovir )vsLopinavir/ritonavir vsRecombinant cytokine gene-derived protein (Novaferon) +.Lopinavir/ritonavir

Arbidol: 200mg TID (PO) Novaferon: 20g TID (INH)Lopinavir/litonavir: 500mg/100mg TID (PO)

The time required for RNA Yin conversion of novel coronavirus in respiratory or blood specimens was compared between treatment groups.

18-65y.o.

193. Randomized, open-label, controlled trial for evaluating of the efficacy and safety of BaloxavirMarboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patientsChiCTR2000029548,

CHINA,The First Affiliated Hospital, Zhejiang University School of Medicine

Interventional RandomisedControlled Open-label

Protease Inhibitor(Lopinavir/ritonavir)Other antiviral(Favipiravir, Baloxavir Marboxil)

Baloxavir MarboxilvsFavipiravirvs Lopinavir/ritonavir

BaloxavirMarboxil: 80mg at Day 1, 4, 7 (PO)Favipiravir: 1600mg loading dose and then 600 mg TID (PO) for no more than 14

Time to viral negativity by Polymerase chain reaction (PCR), time to clinical improvement: Time from start of study drug to hospital discharge or to National Early Warning Score (NEWS) 2 <2 for 24 hours.

18-75y.o.















ChiCTR2000029544 days Lopinavir/ritonavir: 400mg/100mg BID (PO) for 14days.

194. A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir combined with thymosin a1 in the treatment of novel coronavirus pneumonia (COVID-19)ChiCTR2000029541


Interventional RandomisedControlled Open-Label

Protease Inhibitor(Lopinavir/ritonavir, Darunavir/cobicistat)Other agents(Thymosin a1)

Standard treatment + Darunavir/cobicistat + Thymosin a1vsStandard treatment + Lopinavir/ritonavir + Thymosin a1vsStandard treatment + Thymosin a1

Darunavir/ritonavir: 850mg/150mg OD (PO)Thymosin a1: 1.6mg OD (SC)Lopinavir/ritonavir: 400mg/100mg BID (PO)

Time to conversion of 2019-nCoV RNA result from RI sample.

18-65y.o.

195. A randomized, open-label study to evaluate the efficacy and safety of Lopinavir-Ritonavir in patients with mild novel coronavirus pneumonia (COVID-19) ChiCTR2000029539


Interventional RandomisedControlled Open-label

Protease Inhibitor(Lopinavir/ritonavir)

Standard treatment + Lopinavir/ritonavir vsStandard treatment

N/A The incidence of adverse outcome within 14 days after admission: Patients with conscious dyspnea, SpO2 ≤ 94% or respiratory frequency ≥ 24 times / min in the state of resting without oxygen inhalation.

≥18y.o.

196. Efficacy and optimization of antiviral therapy for novel coronavirus pneumonia (COVID-19) patients (http://www.chictr.org.cn/showprojen.aspx?proj=51112 ) ChiCTR2000031196

CHINA,the fifth medical center of PLA general hospital, Beijing

InterventionalNon-randomised Parallel-controlled

Protease Inhibitor(Lopinavir/ritonavir)Interferon

Lopinavir/ritonavir + interferonvsStandard treatment

Lopinavir/ritonavir:1tb BID (PO)Interferon α: 5 million units BID (INH)

Time till the SARS-CoV-2 clearanceMeasure time point of outcome: on day 4, day 7, day 14, et alMeasure method: Reverse Transcription Polymerase chain reaction (PCR).

16-85y.o.

197. A real-world study for lopinavir/ritonavir (LPV/r) and emtritabine (FTC) / Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of novel coronavirus pneumonia (COVID-19) ChiCTR2000029468

CHINA,Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital , Chengdu public health clinical medical center


Protease Inhibitor(Lopinavir/ritonavir)Nucleoside reverse transcriptase inhibitor(Emtritabine (FTC) / Tenofovir alafenamide Fumarate tablets (TAF))

Lopinavir/ritonavir + Emtritabine (FTC) / Tenofovir alafenamide Fumarate tablets (TAF)vsLopinavir/ritonavir only

N/A Patient survival rate. 18-80y.o.

198. Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumoniaChiCTR2000029387

CHINA,Chongqing Public Health Medical Center


Protease Inhibitor(Lopinavir/ritonavir)InterferonOther antiviral(Ribavirin)

Ribavirin + Interferon alpha-1bvsLopinavir/ritonavir + interferon alpha-1bvsRibavirin + Lopinavir/ritonavir + Interferon alpha-1b

N/A The time to 2019-nCoV RNA negativity in patients.

18-65y.o.

199. A randomized, open-label, blank-controlled trial for the efficacy and safety of lopinavir-ritonavir and interferon-alpha 2b in hospitalization patients with novel coronavirus pneumonia (COVID-19) ChiCTR2000029308

CHINA,Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital), China-Japan friendship hospital


Protease Inhibitor(Lopinavir/ritonavir)Interferon

Lopinavir/ritonavir vsStandard treatment

Lopinavir/ritonavir: 400mg/100mg BID (PO)

Clinical improvement time of 28 days after randomizationThe 7-point scale7 points: death, 6 points: admission to Extracorporeal membrane oxygenation (ECMO) and / or mechanical ventilation, 5 points: Hospitalised for non-

≥18y.o.


















invasive ventilation and / or high-flow oxygen therapy, 4 points: hospitalization for oxygen therapy, 3 points: Hospitalisation does not require oxygen therapy, 2 points: discharged but not restored to normal functional status, 1 point: discharged to normal function.

200. Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment (https://clinicaltrials.gov/ct2/show/NCT04276688) NCT04276688

HONG KONGUniversity of Hong Kong, Queen Mary Hospital

Interventional RandomisedOpen-LabelControlled

Protease Inhibitor(Lopinavir/ritonavir)InterferonOther antiviral (Ribavirin)

Lopinavir/ritonavir + Ribavirin + Interferon Beta-1BvsLopinavir/ritonavir + Ribavirin + Interferon Beta-1B

Lopinavir/ritonavir: 400mg/100mg BID for 14 days (PO)Ribavirin: 400mg BID for 14 daysInterferon Beta-1B: 0.25mg (8 million IU) on day 1, 3 and 5 (SC)

Time to negative NPS [Time Frame: Up to 1 month]Time to negative NPS 2019-n-CoV Reverse Transcriptase Polymerase chain reaction (RT-PCR).

≥18y.o.

201. A Randomized, Open-Label, Multi-Centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Novel Coronavirus Pneumonia (COVID-19) Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection (https://clinicaltrials.gov/ct2/show/NCT04261907) ChiCTR2000029603, NCT04261907

CHINA,First Affiliated Hospital of Zhejiang University


Protease Inhibitor(Lopinavir/ritonavir, ASC09/ritonavir)

Standard treatment + ASC09/ritonavirvsStandard treatment + Lopinavir/ritonavir

ASC09/ritonavir: 300mg/100mg BID for 14 days (PO)Lopinavir/ritonavir: 400mg/100mg BID for 14 days (PO)

The incidence of composite adverse outcome [Time Frame: 14 days]Defined as(one of them) SPO2≤ 93% without oxygen supplementation, Ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2) ≤ 300mmHg or Respiratory Rate ≥ 30 breaths per minutes.

18-75y.o.

202. The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection (ELACOI) (https://clinicaltrials.gov/ct2/show/NCT04252885) NCT04252885

CHINA,Guangzhou 8th People's Hospital


Protease Inhibitor(Lopinavir/ritonavir)Other antiviral(Umifenovir)

Standard treatment + Lopinavir/ritonavirvsStandard treatment + UmifenovirvsStandard treatment

Lopinavir/ritonavir: 400mg/100mg BID for 7-14 days (PO)Umifenovir: 200mg TID for 7-14 days (PO)

The rate of virus inhibition [Time Frame: Day 0, 2, 4, 7, 10, 14 and 21]Novel coronaviral nucleic acid is measured in nose / throat swab at each time point.

18-80y.o.

203. Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV (DACO-nCoV) (https://clinicaltrials.gov/ct2/show/NCT04252274) NCT04252274



Protease Inhibitor(Darunavir/cobicistat)

Standard treatment + Darunavir/cobicistatvsStandard treatment

Darunavir/cobicistat: 800mg/150mg OD (PO)

The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7 [Time Frame: 7 days after randomisation].

Any

204. Chinese medicine prevention and treatment program for suspected novel coronavirus pneumonia

CHINA,Hangzhou Xixi Hospital Affiliated to Zhejiang

Interventional RandomisedDouble-blind

Protease inhibitor(Lopinavir/ritonavir)Interferon

Antiviral treatment (interferon + lopinavir/ritonavir) +

Interferon-alpha: 5 million U/time BID (INH)

Relief of clinical symptoms and duration.

14-80y.o.














(COVID-19): a perspective, double-blind, placebo, randomised controlled trialChiCTR2000029517

Chinese Medical University

Placebo-controlled Traditional Chinese Medicine

standard treatment + Traditional Chinese Decoction vsAntiviral treatment (interferon + lopinavir/ritonavir) + standard treatment + Placebo

Lopinavir /ritonavir: 400mg /100mg, 2 BID (PO)Traditional Chinese Decoction (200ml/bag): Huoxiang 9g, Magnolia 9g, Yinhua 9g, Atractylodes 9g, Cicada 6g, Su Ye 6g, Poria 15g, Huai yam 15g BID [9g white lentils+15g Liushenqu (if reduced appetite),.9g pupa live+15g kudzu root (if headache),6g raw ephedra+9g almond (if cough/chest tightness)]

205. A multicenter, randomized, open, parallel controlled trial for the evaluation of the effectiveness and safety of Xiyanping injection in the treatment of common type novel coronavirus pneumonia (COVID-19)Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia (https://clinicaltrials.gov/ct2/show/NCT04275388) NCT04275388, ChiCTR2000030117


Interventional RandomisedMulticentre Open-labelControlled

Protease Inhibitor(Lopinavir/ritonavir)InterferonTraditional Chinese Medicine

Lopinavir/ritonavir + Interferon alpha + XiyanpingvsLopinavir/ritonavir + Interferon alpha

Xiyanping: 10-20ml OD (maximum dose 500mg (20mL)) (IV) for 7-14 days

Clinical recovery time [Time Frame: Up to Day 14]From the beginning of study drug use to fever, respiratory rate, blood oxygen saturation to normal and cough relief, and maintained for at least 72 hours or more, calculated in hours.

18-70y.o.

206. Clinical Controlled Trial for Traditional Chinese Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19) ChiCTR2000029400

CHINA,Wuhan Jinyintan Hospital


Protease Inhibitor(Lopinavir/ritonavir)Traditional Chinese Medicine

Lopinavir/ritonavir + Traditional Chinese MedicinevsLopinavir/ritonavir vsTraditional Chinese Medicine

N/A The rate of remission. ≥18y.o

207. RANDOMISED EVALUATION OF COVID-19 THERAPY (RECOVERY)(https://www.recoverytrial.net/ , https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB/)EudraCT Number: 2020-001113-

UNITED KINGDOM Multiple sites

InterventionalMulticentre Randomised ControlledOpen-label

Protease Inhibitor(Lopinavir/ritonavir) Interferon Corticosteroids Anti-malaria Drug (Hydroxychloroquine)

Standard Treatment vs Lopinavir-Ritonavir + Standard Treatment vs Interferon 1β + Standard Treatment vs

Lopinavir/Ritonavir 400mg/100mg BID (PO) for 10 daysInterferon 1β: 6MIU OD (NEB) for 10 days

All-cause mortality within 28 days of randomisation.

≥18y.o.




https://www.recoverytrial.net/











21 Low-dose Corticosteroids + Standard Treatment vs Hydroxychloroquine + Standard Treatment

Dexamethasone: 6 mg OD (PO or IV) for 10 days Hydroxychloroquine: initial 800 mg, +6h 800 mg, +12h 400 mg, +24h 400 mg, then 400 mg BID for 9 days (PO)

208. A Prospective/Retrospective, Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia(https://clinicaltrials.gov/ct2/show/NCT04255017) NCT04255017


Interventional Randomised Prospective/retrospectiveControlled

Protease Inhibitor(Lopinavir/ritonavir)Other antiviral(Oseltamivir, Umifenovir)

Symptomatic/supportive treatmentvsUmifenovir + supportive treatmentvsOseltamivir + supportive treatmentvsLopinavir/ritonavir + supportive treatment

Umifenovir: 0.2g TID (PO) for 2 weeksOseltamivir: 75mg BID (PO) for 2 weeksLopinavir/ritonavir : 500mg BID (PO) for 2 weeks

Rate of disease remission [Time Frame: two weeks]A: For mild patients: fever, cough and other symptoms relieved with improved lung Computed Tomography (CT); B:For severe patients: fever, cough and other symptoms relieved with improved lung CT,SPO2> 93% or Ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2)>300mmHg (1mmHg=0.133Kpa);Time for lung recovery [Time Frame: two weeks]Compare the average time of lung imaging recovery after 2 weeks of treatment in each group

≥18y.o.

209. A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia NCT04261270

CHINA,Hubei, Department and Institute of Infectious Disease

InterventionalRandomisedControlledSingle-blind

Protease inhibitor(ASC09F/Ritonavir)Other antivirals(Oseltamivir)

ASC09F + OseltamivirvsRitonavir + OseltamivirvsOseltamivir

ASC09F tbs: 400mg bid for 14 daysOseltamivir: 75mg per dayRitonavir: 300mg bid for 14 days

Rate of comprehensive adverse outcome [Time Frame: 14 days]The definition of comprehensive adverse outcome is as follows: SPO2≤93% without oxygen inhalation; Ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2) ≤300mmHg; Respiratory Rate≥30 per minutes without oxygen inhalation.

18-55y.o.

210. Multi-Center Clinical Study on the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19) by Ebastine (http://www.chictr.org.cn/showprojen.aspx?proj=49790 ) , ChiCTR2000030535

CHINA,Wuhan Red Cross Hospital

Interventional RandomisedMulticentreParallel-controlled

Protease Inhibitor (Lopinavir)InterferonAntihistamine(Ebastine)

Ebastine + Interferon-alpha + LopinavirvsInterferon-alpha + Lopinavir

Ebastine: 10mg BID, Interferon-alpha: 5million U BID(INH)Lopinavir 400 mg BID (PO)

Clinical therapeutic courseMeasure method: Fever, respiratory rate, blood oxygen saturation turned to normal and cough relieved for at least 72 hours. Chest Computed Tomography (CT) showed that the inflammation was obviously absorbed, and the nucleic acid of respiratory pathogens was negative twice in a row (the sampling interval was at least 1 day).Pathogenic detectionMeasure time point of outcome: every 3 days

18-75y.o.








Chest CTLaboratory indicators (blood routine, myocardial enzyme spectrum, inflammatory cytokines, etc.)

211. Randomized Controlled Clinical Trials of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19) (https://clinicaltrials.gov/ct2/show/NCT04307693?term=NCT04307693 ) NCT04307693

SOUTH KOREA,Asian Medical Center, University of Ulsan College of Medicine, Seoul


Protease Inhibitor (Lopinavir/ritonavir)Anti-malaria Drug (Hydroxychloroquine)

Lopinavir/ritonavir vs Hydroxychloroquine vs No intervention

Lopinavir/ritonavir 400mg/200mg BID (PO)for 7-10 daysHydroxychloroquine 400mg BID (PO) for 7-10 days

Viral load [Time Frame: hospital day 3, 5, 7, 10, 14, 18]Area under the curve (AUC) of Ct value or viral copies number per mL.

16-99y.o.

212. Trial of Treatments for COVID-19 in Hospitalized Adults(DisCoVeRy) (https://clinicaltrials.gov/ct2/show/NCT04315948?term=NCT04315948 , https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000936-23/FR/) NCT04315948, EudraCT Number: 2020-000936-23

EUROPE,Multiple sites

InterventionalRandomisedMulticentre Parallel-controlledOpen-label

Protease Inhibitor (Lopinavir/ritonavir)Anti-malaria Drug (Hydroxychloroquine)Other antiviral(Remdesivir) Interferon

Standard TreatmentvsStandard Treatment + RemdesivirvsStandard Treatment+ Lopinavir/RitonavirvsStandard Treatment + Lopinavir/Ritonavir + Interferon ß-1avsStandard Treatment +Hydroxychloroquine

Remdesivir: 200mg OD (IV) on Day 1 then100 mg OD (IV) on Day 2-Day 10Lopinavir/Ritonavir: 400/100mg BID (PO) for 14 daysInterferon ß-1a: 44 µg/ 5ml on Day 1, Day 3 and Day 6 (SC)Hydroxychloroquine: 400 mg BID on Day 1 (PO) then 400 mg OD for 9 days (PO)

Percentage of subjects reporting each severity rating on a 7-point ordinal scale [ Time Frame: Day 15 ]Not hospitalised, no limitations on activities; Not hospitalised, limitation on activities; Hospitalised, not requiring supplemental oxygen;Hospitalised, requiring supplemental oxygen; Hospitalised, on non-invasive ventilation or high flow oxygen devices; Hospitalised, on invasive mechanical ventilation or Extracorporeal membrane oxygenation (ECMO); Death.

≥18y.o.

213. Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)( https://clinicaltrials.gov/ct2/ show/NCT04295551?term=NCT04295551 ) NCT04295551

CHINAJiangxi Qingfeng Pharmaceutical Co. Ltd.

InterventionalMulticentreRandomisedOpen-labelParallel-controlled

Protease Inhibitor (Lopinavir/ritonavir)

Traditional Chinese Medicine

Ordinary Covid-19: Lopinavir/ritonavir + Xiyanpingvs Ordinary Covid-19: Lopinavir/ritonavirvsSevere Covid-19: Lopinavir/ritonavir + Xiyanping injection

Xiyanping injection, 10-20ml OD, the maximum daily dose: 20mLLopinavir / ritonavir: 2 BID (PO)

Clinical recovery time [Time Frame: Up to Day 28]The time from study drug use to complete fever reduction and cough recovery is measured in hours.

18-100y.o.

214. A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Chloroquine Versus Lopipinavir/ Ritonavir Plus Oseltamivir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Chloroquine in Mild COVID19 AND Lopipinavir/ Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Chloroquine Versus Favipiravir

THAILAND,Rajavithi Hospital

Interventional Single-centreRandomisedOpen-labelControlled

Protease Inhibitor (Lopinavir/ritonavir, Darunavir/ritonavir)Anti-malaria Drug (Hydroxychloroquine)Other antiviral (Favipiravir, Oseltamivir)

Mild COVID19:Oseltamivir + Hydroxychloroquine vs Darunavir and/ritonavir +oseltamivir vs Lopinavir/ritonavir + oseltamivir vs Conventional quarantine

Moderate to severe

Mild Covid-19: Oseltamivir: 300mg per day (PO) (or 4-6 mg/kg) Hydroxychloroquine: 800 mg per day (PO) for 7-10 days or 400 mg per day(PO) when combined with DarunavirDarunavir: 400

SARS-CoV-2 eradication time [Time Frame: Up to 24 weeks]Eradication of nasopharyngeal SARS-CoV-2.

16-100y.o.

https://clinicaltrials.gov/ct2/show/NCT04295551?term=NCT04295551












Plus Darunavir and Ritonavir Plus Chloroquine in Moderate to Critically Ill COVID19 (https://clinicaltrials.gov/ct2/show/NCT04303299?term=NCT04303299 ) NCT04303299

COVID19:Lopinavir/ritonavir + oseltamivir vs Lopinavir/ritonavir + favipiravirvs Darunavir/ritonavir + oseltamivir + Hydroxychloroquine vs Darunavir/ritonavir + favipiravir + Hydroxychloroquine

mg TID (PO)Ritonavir: 200 mg per day (PO) (or 2.5 mg/kg) + Lopinavir: 800 mg (10 mg/kg) per day (PO)

Moderate - Critically Ill Covid-19: Lopinavir 10 mg/kg per day (PO) for 7-10 daysRitonavir 2.5 mg/kg per day (PO) for 7-10 daysOseltamivir 4-6 mg /kg per day (PO) for 7-10 days Favipiravir: 2400 mg, and 1200 mg (PO) every 8 h on Day 1 then 1200 mg BID (PO)Darunavir: 400 mg TID (PO)Hydroxychloroquine: 400 mg OD (PO) for 7-10 days

215. Evaluation Danoprevir sodium tablets combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19): a randomized, open and controlled trial ChiCTR2000030259

CHINA,Shanghai Changzheng Hospital

Interventional Randomised Open-labelControlled

Protease Inhibitor NS3/4A(Danoprevir/ritonavir)

Standard treatment + Danoprevir/ritonavirvsStandard treatment only

N/A Rate of composite adverse outcomes: SpO2, Ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2), respiratory rate.

18-75y.o.

216. An open, controlled clinical trial for evaluation of ganovo combined with ritonavir and integrated traditional Chinese and Western medicine in the treatment of novel coronavirus infection (COVID-19)Evaluation of Ganovo Combined With Ritonavir in the Treatment of Novel Coronavirus Infection (https://clinicaltrials.gov/ct2/show/NCT04291729) NCT04291729, ChiCTR2000030000

CHINA,Nanchang Ninth Hospital


Protease Inhibitor NS3/4A(Danoprevir/ritonavir)Protease Inhibitor(Lopinavir/ritonavir)InterferonTraditional Chinese MedicineOther Biological Agents (Recombinant cytokine gene-derived protein -Novaferon)

Danoprevir/ritonavir + /- Interferon atomization (for adults)vs Long acting interferon (Pegasys)vsRecombinant cytokine gene-derived protein Spray inhalation (Novaferon)vsLopinavir/ritonavirvsTraditional Chinese Medicine+ Interferon atomization (for adults)

Danoprevir/ritonavir: 100mg/100mg BID (PO) for up to 14daysInterferon: 50μg OD (INH)Long acting Interferon: 180μg, once a week (SC)Novaferon: 20μg, BID for up to 14 days (INH)Lopinavir/ritonavir: 400mg/100mg

Rate of composite adverse outcomes [Time Frame: 14 days]Defined as SPO2≤ 93% without oxygen supplementation, Ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2) rate ≥30 breaths per min without supplemental oxygen.

18-75y.o.












BID for up to 14 days (PO)

217. An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)ChiCTR2000030472

CHINA,Shenyang Sixth People's Hospital


Protease Inhibitor NS3/4A(Danoprevir/ritonavir)

Standard treatment + Danoprevir/ritonavirvsStandard treatment

N/A Rate of composite adverse outcomes: SPO2, Ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2) and respiratory rate.

18-75y.o.

218. A medical records based study for optimization and evaluation of the comprehensive diagnosis and treatment of novel coronavirus pneumonia (COVID-19) and the assessment of risk factors for severe pneumonia ChiCTR2000030095



Therapy-General N/A N/A Detection of virus nucleic acid. N/A

219. Study for Novel Coronavirus Pneumonia (NCP) (https://clinicaltrials.gov/ct2/show/NCT04283396) NCT04283396

CHINA,Wuhan Union Hospital


Therapy-General Patients taking oxygen therapy, antiviral therapy, antibiotics, hormones, globulin

N/A Recovery [Time Frame: up to 24 weeks]Number of patients recover from novel coronavirus pneumonia.

18-90y.o.

220. Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus (2019-nCoV) (https://clinicaltrials.gov/ct2/show/NCT04292327) NCT04292327

CHINA,Wuhan Infectious Diseases Hospital


Therapy-General N/A N/A Mortality [Time Frame: 28 day]The mortality of COVID-19 in 28 daysThe time interval of Nucleic acid detection become negative [Time Frame: 28 day]The time interval of COVID-19 form nucleic acid confirmed to the nucleic acid detection turn into negative.

N/A

221. A medical records based analysis for antiviral therapy effect on novel coronavirus pneumonia COVID-19 patients ChiCTR2000030391

CHINA,Lishui Central Hospital


Therapy-General Patients who received antiviral therapy

N/A Cure rate, Virus negative rate, Time of virus negative.

N/A

222. Traditional Chinese Medicine for Severe COVID-19(https://www.clinicaltrials.gov/ct2/show/NCT04323332 ) NCT04323332

CHINA,Xiyuan Hospital of China Academy of Chinese Medical Sciences

Interventional Non-randomised Parallel-controlledOpen-label


Tradtional Chinese Medicine + standard treatmentvsStandard treatment

N/A Length of hospital stay (days) [Time Frame: First treatment date up to 3 months]

≤85y.o.

223. Study for the efficacy of Kangguan No. 1-3 prescription in the treatment of novel coronavirus pneumonia (COVID19) ChiCTR2000030215


InterventionalRandomisedSingle-centreControlled


Standard treatment + Kanguan No. 1vsStandard treatment + Kanguan No. 2vsStandard treatment + Kanguan No. 3vs Standard treatment only in severe, mild and general patients

Kanguan No. 1 (PO) ODKanguan No. 2 (PO) BIDKanguan No. 3 (PO) OD

Vital signs: breathing, body temperature (armpit temperature)Measure time point of outcome: Before entering the group, at the end of the sampleBlood routineMeasure time point of outcome: Before entering the group, at the end of the sampleC-reactive proteinMeasure time point of outcome: Before entering the group, at the end of the sample

18-65y.o.



















Liver and kidney function testMeasure time point of outcome: Before entering the group, at the end of the sample Myocardial enzyme contentMeasure time point of outcome: Before entering the group, at the end of the sampleESRMeasure time point of outcome: Before entering the group, at the end of the sampleT cell subsetsMeasure time point of outcome: Before entering the group, at the end of the sample CytokineMeasure time point of outcome: Before entering the group, at the end of the sample Liver, gallbladder, thyroid, and lymph node imagingMeasure time point of outcome: Before entering the group, at the end of the sample Chest Computed TomographyMeasure time point of outcome: Before entering the group, at the end of the sample Infectious disease testMeasure time point of outcome: Before entering the group, at the end of the sample.

224. A parallel, randomized controlled clinical trial for the efficacy and safety of PediatricHuatanzhike granules (containing ipecacuanha tincture) in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)ChiCTR2000030022

CHINA,First Affiliated Hospital of Anhui Medical University, Wuhan mobile cabin hospital, Binhu hospital of the first people's hospital of Hefei, The second people's hospital of Hefei, Suzhou hospital affiliated to Anhui medical university, Feidong hospital.

InterventionalRandomisedControlled


Standard treatment + pediatricHuatanzhike granulesvs Standard treatment

N/A COVID-19 nucleic acid detection time from positive to negative (respiratory secretion) or (3,5,7,10 days from positive to negative rate);Lung Computed Tomography observation of inflammation absorption; Proportion of cases with progressive disease

18-80y.o.

225. A randomized, open-label, controlled trial for the safety and efficiency of Kesuting syrup and Keqing capsule in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19) ChiCTR2000029991

CHINA,The First Affiliated Hospital of Nanchang UniversityFoshan 4th People's Hospital



Standard treatment + Kesuting syrupvsStandard treatment + Keqing capsulevsStandard treatment only

Kesuting syrup: 20mL TID (PO) Keqing capsule: 3tb TID (PO)

CoughTime of disappearance of cough

18-75y.o.

226. Efficacy and safety of honeysuckle oral liquid in the treatment of novel

CHINA,Hubei Hospital of

InterventionalMulticentre


Standard treatment + low dose honeysuckle

Low dose honeysuckle:

Recovery time, Pneumonia Severity Index (PSI) score.

18-65y.o.









coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trialChiCTR2000029954, ChiCTR2000030545

Traditional Chinese Medicine, Union Hospital, Suizhou Central Hospital, The third people's Hospital of Hubei Province, Xiaogan first people's Hospital, Wuhan Sixth People's Hospital

RandomisedOpen-labelControlled

vsStandard treatment + high dose honeysucklevsStandard treatment only

60mL TID (PO)High dose honeysuckle:180 mL TID (PO)

227. A randomized controlled trial for honeysuckle decoction in the treatment of patients with novel coronavirus (COVID-19) infectionChiCTR2000029822

CHINA,Nanjing Second Hospital



Honeysuckle decoction vsPlacebo

Honeysuckle decoction:100mL BID (PO) for 14 days [30g honeysuckle in 200ml decoction] <16 y.o: 0.5g/kg honeysuckle

Rate of cureUntil Polymerase chain reaction (PCR) negative

0-100y.o.

228. Effect evaluation and prognosis of Chinese medicine based on Novel Coronavirus Pneumonia (COVID-19) ChiCTR2000029747

CHINA,The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, The First Affiliated Hospital Anhui Medicine University, Sixian Hospital of Traditional Medicine, Anhui Provincial Hospital



Traditional Chinese MedicinevsStandard treatment

N/A Chest Computed Tomography, Routine blood test, Liver and renal function, TCM syndrome.

12-80y.o.

229. Clinical observation and evaluation of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in Hubei 672 Orthopaedics Hospital of Integrated Chinese＆Western Medicine (http://www.chictr.org.cn/showprojen.aspx?proj=50986 ) ChiCTR2000030810

CHINA,Hubei 672 Orthopaedics Hospital of Integrated Chinese＆Western Medicine



Oral medicine(traditional medicine)vsOral medicine (anti viral)

N/A Average discharge time, White blood cells (WBC), ALT, AST, gama-GT, BUN, Cr, CK-MB, Turn serious/crisis ratio.

≥18y.o.

230. Observation Of Clinical Efficacy And Safety Of Bufonis Venenum Injection In The Treatment Of Severe Novel Coronavirus Pneumonia (COVID-19) (http://www.chictr.org.cn/showprojen.aspx?proj=50778 ) ChiCTR2000030704

CHINA,The first people's Hospital of Jiangxia District, Wuhan

Interventional- RandomisedParallel-controlled


Bufonisvenenum injectionvsPlacebo

Placebo:0.9% Normal Saline (IV)

PO2/FiO2, ROX INDEX 7-90y.o.

231. Efficacy and safety of Ma-Xing-Gan-Shi decoction in the treatment of novel coronavirus pneumonia (COVID-19) (http://www.chictr.org.cn/showprojen.aspx?proj=44213 ) ChiCTR2000030522

CHINA,Wuhan Red Cross Society Hospital, Hospital of Chengdu University of Traditional Chinese Medicine,Chengdu Fifth People's Hospital

Interventional Randomised MulticentreParallel-controlled


Ma-Xing-Gan-Shi decoction + Conventional Western Medicine TreatmentvsPlacebo + Conventional Western Medicine Treatment

N/A Time to Clinical Recovery. 18-75y.o.















232. Zedoary Turmeric Oil for Injection in the treatment of Novel Coronavirus Pneumonia (COVID-19): a randomized, open, controlled trial (http://www.chictr.org.cn/showprojen.aspx?proj=50586 ) ChiCTR2000030518

CHINA,The Second Affiliated Hospital of Wenzhou Medical University



Zedoary Turmeric Oil vsStandard Treatment

Zedoary Turmeric Oil: 0.2 g (4 vials) OD (IV) for 7 days

Real-time fluorescent RT-PCR detection of pharyngeal swab were used to detect the negative conversion rate of the new coronavirus nucleic acid (tested after the end of medication) and the negative conversion time(measured every other day after the start of medication, determined according to clinical needs), Time to clinical improvement, Change in size of lesion area by chest Computed Tomography, Time to fever subsidence, defined as the time at which a subject with fever at enrollment has returned to normal temperature for at least 72 hours.

≥18y.o.

233. Traditional Chinese Medicine 'Zang-Fu Point-pressing' massage for children with novel coronavirus pneumonia (COVID-19)ChiCTR2000030324

CHINA,Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences

Interventional RandomisedSingle-centre Controlled

Traditional Chinese Medicine(Acupuncture)

“Zang-Fu Point-pressing” groupvsControl group

N/A Temperature, Respiratory symptoms.

≥2y.o.

234. Traditional Chinese medicine Ma-Xing-Shi-Gan-Tang and Sheng-Jiang-San in the treatment of children with novel coronavirus pneumonia (COVID-19) ChiCTR2000030314

CHINA,Xiangyang Central Hospital



Standard treatment + Ma-Xing-Shi-Gan-Tang + Sheng-Jiang-San

N/A Temperature, Respiratory symptoms.

≥1y.o.

235. Efficacy of Traditional Chinese Medicine in the Treatment of Novel Coronavirus Pneumonia (COVID-19): a Randomized Controlled TrialChiCTR2000030288

CHINA,Wuhan Jinyintan Hospital



Standard treatment + traditional Chinese formulavsStandard treatment only

N/A The time to 2019-nCoV RNA negativity in patients.

≥18y.o.

236. Efficacy and Safety of Jing-Yin Granule in the treatment of novel coronavirus pneumonia (COVID-19) wind-heat syndrome ChiCTR2000030255

CHINA,Leishenshan Hospital



Standard treatment + Jing-Yin GranulevsStandard treatment only

Jing-Yin Granule: 2 bags/time TID

Clearance rate and time of main symptoms (fever, fatigue, cough).

18-75y.o.

237. Clinical Reseach of Acupuncture in the treatment of Novel Coronavirus Pneumonia (COVID-19) ChiCTR2000030225

CHINA,Wuhan Leishenshan Hospital.



Standard treatment + AcupuncturevsStandard treatment only

N/A Length of hospital stay, Discharge time of general type, Discharge time of severe type.

18-80y.o

238. Study for evaluation of integrated traditional Chinese and Western Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19)ChiCTR2000030219

CHINA,First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

Interventional Single-arm


Standard treatment + Traditional Chinese Medicine

N/A Clinical symptoms, TCM syndrome.

8-91y.o.

239. Clinical Study on Syndrome Differentiation of TCM in Treating Severe and Critical novel coronavirus pneumonia (COVID-

CHINA,Hubei Provincial Hospital of Integrated Traditional Chinese and



Standard treatment + Traditional Chinese MedicinevsStandard treatment only

N/A TCM symptom score, Becomes negative time of COVID-19, Cure / mortality rate.

≥18y.o.























19)ChiCTR2000030188

Western Medicine

240. Comparative study for integrate Chinese and conventional medicine the the treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province ChiCTR2000029960

CHINA,The First Affiliated Hospital of Hu'nan University of traditional Chinese Medicine




N/A TCM syndrome. N/A

241. A Randomized Controlled Trial for Qingyi No. 4 Compound in the treatment of Convalescence Patients of Novel Coronavirus Pneumonia (COVID-19) ChiCTR2000029947

CHINA,Wuhan Pulmonary Hospital, Wuhan Third People's Hospital, Hefei Infectious Disease Hospital, Jiangsu Province Infectious Disease Hospital, The First Affiliated Hospital of Xi'an Jiaotong University



Standard treatment + Qingyi No. 4 CompoundvsStandard treatment

N/A Lung function. 18-75y.o.

242. A randomized controlled trial for Traditional Chinese Medicine in the treatment for Novel Coronavirus Pneumonia (COVID-19)ChiCTR2000029941

CHINA,Wuhan Pulmonary Hospital, Wuhan Third People's Hospital, Hefei Infectious Disease Hospital, Jiangsu Province Infectious Disease Hospital, The First Affiliated Hospital of Xi'an Jiaotong University



Standard treatment + Traditional Chinese MedicinevsStandard treatment

N/A Number of worsening events. 18-75y.o.

243. A multicenter, randomized, controlled trial for integrated Chinese and western medicine in the treatment of ordinary novel coronavirus pneumonia (COVID-19) based on the ' Internal and External Relieving -Truncated Torsion' strategy ChiCTR2000029869, ChiCTR2000029777

CHINA,Huangshi Hospital of traditional Chinese Medicine, Tongji Hospital of Huazhong University of science and technology, LaoHeKouTradiational Chinese Medicine Hospital



Standard treatment + ‘Truncated Torsion' FormulavsStandard treatment

N/A 14 day outcome of the subjects, including: recovery, improvement, turning critical, death.

18-80y.o.

244. A randomized, open and controlled clinical trial for traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) ChiCTR2000029855

CHINA,The First Affiliated Hospital of Medical College of Zhejiang University

Interventional RandomisedControlledOpen-label


Traditional Chinese Medicine Qingfei prescription treatmentvsTraditional Chinese Medicine clear lung prescription and compound Houttuynia mixture treatment

N/A TCM symptom score, Antifebrile time, The time and rate of transition of new coronavirus to Yin.

18-75y.o.

245. Traditional Chinese Medicine for novel coronavirus pneumonia (COVID-19) (http://www.chictr.org.cn/showprojen.aspx?proj=50662 ) ChiCTR2000030864

CHINA Xiangyang No. 1 people's Hospital



Western medicine + QingfeiPaidu decoction

N/A 2019-ncov-RNA, Chest Computed Tomography, Blood biochemistry, TCM symptom.

All ages

246. Clinical Trial for Integrated CHINA, Interventional Traditional Chinese Standard treatment + N/A Time for fever reduction, Time 0-18y.o.




















Chinese and Western Medicine in the Treatment of Children with Novel Coronavirus Pneumonia (COVID-19) ChiCTR2000029814

Children's Hospital of Fudan University

RandomisedControlled

Medicine Traditional Chinese MedicinevsStandard treatment

of nucleic acid negative, Severe conversion rate, Improvement time of respiratory symptoms.

247. Clinical Trial for Tanreqing Capsules in the Treatment of Novel Coronavirus Pneumonia (COVID-19) ChiCTR2000029813




Standard treatment + Tanreqing CapsulesvsStandard treatment

Tanreqing Capsules 3 capsules TID (PO)

Time of viral nucleic acid turns negativeAfter the subject's condition is significantly improved, two or more new coronavirus pneumonia virus nucleic acid tests (with an interval of more than 24 hours) are performed, and the test is negative for two consecutive times. The negative time is the time when the first test result is negative.Antipyretic timeObserve once every day during the treatment period at 8 o'clock, 12 o'clock, 16 o'clock, and 20 o'clock.

18-75y.o.

248. Clinical study for the integration of traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)ChiCTR2000029790

CHINA,Shanghai Pulmonary Hospital




N/A TCM symptoms efficacy. 18-80y.o.

249. Randomized controlled trial for TCM syndrome differentiation treatment impacting quality of life of post-discharge patients with novel coronavirus pneumonia (COVID-19) ChiCTR2000029789

CHINA,The First Affiliated Hospital of He'nan University of Chinese Medicine, Zhengzhou Sixth People's Hospital, Nanyang Central Hospital, The First Affiliated Hospital of Nanyang Medical College, Zhumadian Central Hospital, Jiaozuo Hospital of Traditional Chinese Medicine



Standard treatment + Traditional Chinese MedicinevsStandard treatment + Placebo

N/A St. George's Respiratory Questionnaire.

18-90y.o.

250. Traditional Chinese medicine cooperative therapy for patients with novel coronavirus pneumonia (COVID-19): a randomized controlled trial ChiCTR2000029788

CHINA,The First Clinical Hospital of Beijing University of Chinese Medicine (Dongzhimen Hospital)




N/A Antipyretic time, Pharyngeal swab nucleic acid negative time, Blood gas analysis, Traditional Chinese medicine syndrome score.

18-80y.o.

251. A multicenter, randomized, open and controlled trial for the efficacy and safety of Kang-Bing-Du granules in the treatment of novel coronavirus pneumonia (COVID-19) ChiCTR2000029781

CHINA,Wuhan Puren Hospital, Huanggang Central Hospital, Xishui County People's Hospital, Huangmei County People's Hospital, Xiaogan Central



Standard treatment + Kang-Bing-Du granules (Lizhu) vsStandard treatment

N/A Disappearance rate of fever symptoms.

≥18y.o.


















Hospital252. A multicenter, randomized, open,

controlled trial for the efficacy and safety of Shen-Qi Fu-Zheng injection in the treatment of novel coronavirus pneumonia (COVID-19 ) ChiCTR2000029780

CHINA,Huanggang Central Hospital, Xishui County People's Hospital, Huangmei County People's Hospital, Wuhan Puren Hospital, Qichun County People's Hospital, Xiaogan Central Hospital

Interventional Multicentre Randomised Controlled


Standard treatment + Shen-Qi Fu-Zheng injection vsStandard treatment

N/A Recovery time. ≥18y.o.

253. Clinical Study for Traditional Chinese Medicine Combined With Western Medicine in Treatment of Novel Coronavirus Pneumonia (COVID-19) ChiCTR2000029778

CHINA,Shanghai Public Health Clinic Center

Interventional Non-randomisedControlled


Standard treatment + herbal medicine vsStandard treatment + QFPD decoction vsStandard treatment + SFJD capsulevsStandard treatment

N/A Length of hospital stay, fever clearance time.

15-85y.o.

254. A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian oral solution in the treatment of ovel coronavirus pneumonia (COVID-19) ChiCTR2000029605

CHINA,Tongji Hospital, Infectious Disease Hospital of Heiongjiang Province



Standard treatment + Low dose Shuang-Huang-Lian.vs Standard treatment + Medium dose Shuang-Huang-LianvsStandard treatment + High dose Shuang-Huang-LianvsStandard treatment

Low dose: 2 bottles/time TIDMedium dose: 4 bottles/time TIDHigh dose: 6 bottles/time TID

Time to disease recovery. ≥18y.o.

255. An open, prospective, multicenter clinical study for the efficacy and safety of Reduning injection in the treatment of ovel coronavirus pneumonia (COVID-19) ChiCTR2000029589

CHINA,WenZhou Central Hospital, Yichang Third People's Hospital, Huai'an NO 4 People's Hospital, Affiliated Hospital of Xuzhou Medical University, The Fourth People's Hospital of Lianyungang



Standard treatment + Reduning injectionvsStandard treatment

Ν/Α Antipyretic time. ≥18y.o.

256. Recommendations of Integrated Traditional Chinese and Western Medicine for Diagnosis and Treatment of Novel Coronavirus Pneumonia (COVID-19) in Sichuan ProvinceChiCTR2000029558

CHINA,Hospital of Chengdu University of Traditional Chinese Medicine



Integrated Traditional Chinese and Western Medicine

N/A Blood routine tests, urine routine tests, C-reactive protein, Procalcitonin, Erythrocyte sedimentation rate.

N/A

257. Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19): a perspective, double-blind, placebo, randomised controlled trial ChiCTR2000029518

CHINA,Xixi Hospital of Hangzhou



Standard treatment + Traditional Chinese Medicine (ordinary group)vsStandard treatment only (ordinary group)

N/A Recovery time, Ratio and time for the general type to progress to heavy, Ratio and time of severe progression to critical or even death.

14-80y.o.



















vsStandard treatment + Traditional Chinese Medicine (severe group)vsStandard treatment only (severe group)

258. A Randomized Controlled Trial for Integrated Traditional Chinese Medicine and Western Medicine in the Treatment of Common Type Novel Coronavirus Pneumonia (COVID-19)ChiCTR2000029461

CHINA,Xinhua affiliated hospital, Hubei Provincial Hospital of Integrated Chinese and Western Medicine



Standard treatment + Traditional Chinese DecoctionsvsStandard treatment only

N/A Pulmonary function, Antipyretic time, Time of virus turning negative.

18-70y.o.

259. Combination of traditional Chinese medicine and western medicine in the treatment of common type novel coronavirus pneumonia (COVID-19) ChiCTR2000029439

CHINA,Hubei integrated traditional Chinese and Western Medicine Hospital , Wuhan hospital of TCM



Standard treatment + Traditional Chinese DecoctionsvsStandard treatment

N/A Antipyretic time, Time of virus turning negative,

N/A

260. A randomized controlled trial of integrated TCM and Western Medicine in the treatment of severe novel coronavirus pneumonia (COVID-19) ChiCTR2000029438

CHINA,Hubei integrated traditional Chinese and Western Medicine Hospital




N/A CURB-65 score, Pneumonia Severity Index (PSI) score, Mechanical ventilation time, Length of stay in hospital.

N/A

261. A single arm study for evaluation of integrated traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19) ChiCTR2000029436

CHINA,8sites




N/A Duration of Polymerase chain reaction normalisation, Clinical symptom score.

N/A

262. A Real World Study for the Efficacy and Safety of Large Dose Tanreqing Injection in the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19)ChiCTR2000029432

CHINA,The First Affiliated Hospital of Guangzhou University of Chinese Medicine



Tanreqing injection (IV) Tanreqing injection: add in 500ml of 5% glucose injection or 0.9% sodium chloride (no more than 60 drops per minute), 1-2 times/day; 40ml /day is recommended [no more than 80ml /day] (IV)

Time for body temperature recovery, Chest X-ray absorption.

18-75y.o.

263. A prospective comparative study for Xue-Bi-Jing injection in the treatment of novel coronavirus pneumonia (COVID-19)ChiCTR2000029381

CHINA,21 sites

InterventionalNon-randomisedControlled


Xue-Bi-Jing injectionvsStandard treatment

N/A Pneumonia severity index (PSI). 18-75y.o.

264. Shen-Fu injection in the treatment of severe novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial ChiCTR2000030043

CHINA,16 Sites

Interventional RandomisedMulticentreOpen-labelControlled


Standard treatment + Shen-Fu injectionvsStandard treatment only

N/A Pneumonia severity index (PSI), Incidence of new organ dysfunction.

18-75y.o.

265. Traditional Chinese Medicine in CHINA, Interventional Traditional Chinese Standard treatment + N/A Body temperature, TCM 18-85y.o.























the treatment of novel coronavirus pneumonia (COVID-19): a multicentre, randomized controlled trialChiCTR2000030034

The first affiliated hospital of wenzhou medical university, Wenzhou central hospital, The first people's hospital of Wenling, Shaoxing people's hospital, Lishuizhongyiyiyuan, People's hospital of Quzhou, Ruian people's hospital

RandomisedMulticentreOpen-labelControlled

Medicine Traditional Chinese MedicinevsStandard treatment

syndrome integral, Murray lung injury score, The transition time of novel coronavirus nucleic acid, MuLBSTA score (90-day mortality in patients with viral pneumonia).

266. Optimization Protocal of Integrated Traditional Chinese and Western Medicine in the Treatment for Novel Coronavirus Pneumonia (COVID-19) ChiCTR2000030003

CHINA,Hospital of Chengdu University of Traditional Chinese Medicine



Traditional Chinese Medicine prescription No. 1 and 2vsGankeshuangqing capsulevsShuanghuanglian oral liquid

N/A Hospital stay, Discharge rate, Site-specific hospital metastasis rate or severe conversion rate, Body temperature normalization time, Clinical symptoms disappearance rate.

N/A

267. Liu-Zi-Jue Qigong and Acupressure Therapy for Pulmonary Function and Quality of Life in Patient with Severe novel coronavirus pneumonia (COVID-19): A Randomized Controlled Trial ChiCTR2000029994

CHINA,Huangshi city hospital of TCM


Traditional Chinese Medicine(Acupressure)

Standard treatment + Acupressure + Liuzijue qigongvsStandard treatment

N/A Lung function, Activities of Daily Living (ADL) scale, 6min walk.

18-80y.o.

268. Prognosis Investigation and Intervention Study on Patients with novel coronavirus pneumonia (COVID-19) in recovery period Based on Community Health Management (http://www.chictr.org.cn/showprojen.aspx?proj=50793 ) ChiCTR2000030720

CHINA,Hubei Provincial Hospital of TCM



Traditional Chinese Medicine (Six Nobles Decoction + liriope and schisandra/ notoginseng and peach kernel/ Glehnialittoralis and radix rehmanniae)vsWestern medicine standard treatment

N/A Medical imaging improvement rate in patients during recovery period.

18-65y.o.

269. Babaodan Capsule used for the adjuvant treatment of severe novel coronavirus pneumonia (COVID-19) ChiCTR2000029769

CHINA,Enze Hospital of Taizhou Enze Medical Center (Group)



Standard treatment + Ba-Bao-Dan capsulevsStandard treatment only

Ba-Bao-Dan capsule: 6 capsules BID (PO)

28-day survival, Inflammatory factor levels.

18-80y.o.

270. The efficacy of traditional chinese medicine on Novel Coronavirus Pneumonia (COVID-19) patients treated in square cabin hospital: a prospective, randomized controlled trialChiCTR2000029763

CHINA,Wuhan Keting Square Cabin Hospital




N/A Rate of conversion to severe or critical illness.

18-75y.o.

271. A randomized, open, parallel-controlled clinical trial on the efficacy and safety of Jingyebaidu granules in treating novel coronavirus pneumonia (COVID-19) ChiCTR2000029755




Standard treatment + Jinyebaidu granulevsStandard treatment

Jinyebaidu granule: 1-2 bags TID (PO)

Validity observation index. ≥18y.o.

272. Chinese Herbal medicine for Severe nevel coronavirus pneumonia (COVID-19): a Randomized Controlled Trial

CHINA,Hubei Provincial Hospital of Integrated Chinese and Western




N/A Critically ill patients (%). ≥18y.o























ChiCTR2000029418 Medicine 273. Traditional Chinese medicine

cooperative therapy for patients with Novel coronavirus pneumonia (COVID-19) and its effect on spermatogenesis: a randomized controlled trialChiCTR2000030027

CHINA,Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Huangshi Traditional Chinese Medicine Hospital of Hubei Province, Hubei Provincial Hospital of Integrated&Western Medicine

InterventionalSingle-armMulticentre


Standard treatment + Traditional Chinese Medicine

N/A Release rate of discharge standards for isolation, Change in Critical Illness, Traditional Chinese medicine syndrome score.

≥18y.o.

274. Ba-Bao-Dan in the adjuvant therapy of novel coronavirus pneumonia (COVID-19) patientsChiCTR2000029819

CHINA,Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

InterventionalSingle-armMulticentre


Standard treatment + Ba-Bao-DanvsStandard treatment

N/A Clinical and laboratory indicators, Viral load, Chest Computed Tomography, Serum cell factor.

≥18y.o.

275. Efficacy and safety of Xue-Bi-Jing injection in the treatment of severe cases of novel coronavirus pneumonia (COVID-19)ChiCTR2000030388

CHINA,Jingzhou first people's Hospital



Standard treatment + Xue-Bi-Jing (IV)vsStandard treatment

Xue-Bi-Jing: 50ml BID (IV)

The percentage of patients who convert to moderate one within 14 days, The rate of shock, Endotracheal intubation ratio, Time spent on the ventilator, Mortality.

18-80y.o.

276. Study for the Effectiveness and Safety of Yi-Qi Hua-shiJie-Du-Fang in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)ChiCTR2000030479

CHINA,Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine, Wuhan Jiangxia District First People's Hospital, Wuhan Jiangxia District Traditional Chinese Medicine Hospital



Standard treatment + YiqiHuashiJiedu FangvsStandard treatment

Yiqi Huashi Jiedu Fang 300mL

Lasting time of fever, lasting time of novel coronavirus pneumonia virus nucleic acid detected by Reverse transcription polymerase chain reaction (RT-PCR) and negative result rate of the novel coronavirus disease nucleic acid.

18-75 y.o.

277. A randomized parallel controlled trial for LIUSHENWAN in Treatment of Novel Coronavirus Pneumonia (COVID-19)ChiCTR2000030469

CHINA,Leishenshan Hospital



Standard treatment + Liu-Shen-WanvsStandard treatment

N/A Fever clearance time, Effective rate of TCM symptoms,

18-65 y.o.

278. An observational study for Xin-Guan-1 formula in the treatment of novel coronavirus pneumonia (COVID-19) ChiCTR2000029637

CHINA,Wuhan Hankou hospital



Standard treatment + Xinguan-1 formulavsStandard treatment

N/A Completely antipyretic time: defined as the body temperature return to normal for over 24 hours.Time to remission/disappearance of primary symptoms: defined as the number of days when the three main symptoms of fever, cough, and shortness of breath are all relieved / disappeared

N/A

279. A clinical observational study for Xin-Guan-2 formula in the treatment of suspected novel coronavirus pneumonia (COVID-19) ChiCTR2000029628

CHINA,Higher Education Mega Center Branch of Guangdong Provincial Hospital of Chinese Medicine



Standard treatment + Xin-Guan-2 formulavsStandard treatment

N/A Time to completely antipyretic time: completely antipyretic was defined as the body temperature return to normal for over 24 hours.Main symptom

N/A






















relief/disappearance time: defined as the days when the three main symptoms of fever, cough and shortness of breath all remission/disappear.

280. A real world study for traditional Chinese Medicine in the treatment of novel coronavirus pneumonia (COVID-19) ChiCTR2000029624


ProspectiveObservational Study


Patients receiving Traditional Chinese Medicine

N/A Time for body temperature recovery, Chest Computed Tomography absorption.

N/A

281. Evaluate the effectiveness of Traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)ChiCTR2000029896

CHINA,Affiliated Hospital of Changchun University of traditional Chinese Medicine



Patients received Standard treatment + Traditional Chinese Medicine

N/A Conversion rate of mild and common type patients to severe type, Mortality Rate.

N/A

282. A single arm study for combination of traditional Chinese and Western Medicine in the treatment of novel coronavirus pneumonia (COVID-19) ChiCTR2000029437

CHINA,Hubei integrated hospital of traditional Chinese and Western Medicine



Different types of patients receiving standard treatment + Traditional Chinese Medicine

N/A All available outcomes. N/A

283. Study for the key technique of integrative therapy of Novel Coronavirus Pneumonia (COVID-19): the TCM symptoms and treatment regulation *ChiCTR2000030468

CHINA,Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Shandong Province Chest Hospital , Jinan Infectious Disease Hospital, Qingdao Chest Hospital, Liaocheng Infectious Disease Hospital



4 Groups: Taking Chinese medicine preventive decoction group, General prevention methods group, TCM syndrome differentiation treatment+ Western medicine treatment group, Western medicine treatment only group

N/A Disease incidence, Duration of Polymerase chain reaction (PCR) normalisation.

>2 y.o.

284. A retrospective cohort study for integrated traditional Chinese and western medicine in the treatment of 1071 patients with novel coronavirus pneumonia (COVID-19) in Wuhan (http://www.chictr.org.cn/showprojen.aspx?proj=50867) ChiCTR2000030719

CHINA,Wuhan Hospital of Integrated Traditional Chinese and Western Medicine



Integrated traditional Chinese and western medicine vsWestern medicine standard treatment

N/A Mortality rate, Common-severe conversion rate, Length of hospital stay.

N/A

285. Retrospective study for integrate Chinese and conventional medicine treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province (http://www.chictr.org.cn/showprojen.aspx?proj=50549 ) ChiCTR2000030492

CHINA,The First Affiliated Hospital of Hunan University of traditional Chinese Medicine



Integrate Chinese + conventional medicine treatmentvsWestern medicine standard treatment

N/A TCM syndrome. N/A

286. A randomized controlled trial for the efficacy of Dao-Yin in the prevention and controlling novel coronavirus pneumonia (COVID-19) ChiCTR2000029978

CHINA,Yueyang Hospital of Integrated Traditional Chinese and Western Medicine,



Conventional treatment vs Conventional treatment plus Dao Yin

N/A Length of hospital stay. 18-60 y.o.




















287. Community based prevention and control for Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in the isolate suspected and confirmed population ChiCTR2000029601

CHINA,Hubei Provincial Hospital of TCM


Traditional Chinese MedicineHealth education

Health education + basic treatment of western medicine vs Health education + basic treatment of western medicine + dialectical treatment of traditional Chinese medicine

N/A The negative conversion ratio, The proportion of general patients with advanced severe disease, Confirmed rate of suspected cases.

18-65 y.o.

288. Clinical Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19) ChiCTR2000029751

CHINA,The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine

Observational study Traditional Chinese Medicine

Suspected patients: Routine respiratory disease treatmentvs Oral Chinese medicine treatment based on control group

Common COVID-19 patients: Treatment according to the guidelines vs Oral Chinese medicine treatment + standard treatment

Severe COVID-19 patient:Oral Chinese medicine treatment + standard treatment

N/A Blood routine examination, C-reactive protein, Procalcitonin, Chest Computed Tomography, Liver and Kidney function.

18-85 y.o.

289. Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19): a perspective, sing-arm trial ChiCTR2000029578

CHINA,Zhejiang Chinese Medical University



Integrated Traditional Chinese and Western medicine

N/A Cure rate, Cure time, The rate and time at which the normal type progresses to the heavy type, Rate and time of progression from heavy to critical type and even death.

N/A

290. A Comparative Study for the Effectiveness of ''triple energizer treatment'' Method in Repairing Lung Injury in Patients with Novel coronavirus pneumonia (COVID-19)ChiCTR2000030389

CHINA,Hubei Provincial Hospital of TCM, Tian You Hospital, Xiang Yang Hospital of TCM, Jingmen Hospital of TCM, Renmin Hospital of Hanchuan, Wuhan Hospital of TCM, Huangshi Hospital of TCM, The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture



Standard treatment + “Triple Energizer Treatment”vsStandard treatment

N/A Lung Computed Tomography, TCM symptoms.

≥18y.o.

291. Clinical Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)*ChiCTR2000030315

CHINA,Wuhan Thunder God Mountain Hospital



Patients receiving traditional Chinese and western medicine treatment schemes

N/A Critically ill patients (%), Mortality Rate.

≥18y.o.
















292. Multiomics study and emergency plan optimization of spleen strengthening clearing damp and stomach therapy combined with antiviral therapy for novel coronavirus pneumonia (COVID-19) ChiCTR2000030305

CHINA,The fourth affiliated hospital of Zhejiang University school of medicine



Patients receiving traditional Chinese and anti-viral therapy

N/A Blood RNA. 18-90y.o.

293. A Medical Based Retrospective Real World Study for Assessment of Effectiveness of Comprehensive Traditional Chinese Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19) ChiCTR2000030163

CHINA,Yueyang Hospital of Integrated Traditional Chinese Medicine and Western Medicine Affiliated to Shanghai University of Traditional Medicine



Patients who received Western Medicine and Traditional Chinese Medicine treatment

N/A Cure rate, Duration of hospitalisation, Days of treatment.

0-100y.o.

294. Clinical Study of Tetrandrine Tablets Adjuvant Treatment With COVID-19 (https://clinicaltrials.gov/ct2/show/NCT04308317?term=NCT04308317) NCT04308317

CHINAHenan Provincial People's Hospital



Tetrandrine vs Standard Treatment

Tetrandrine 60mg OD for 1week

Survival rate [Time Frame: 12 weeks]Death event

18-75 y.o.

295. Clinical Application and Theoretical Discussion of Fuzheng Qingfei Thought in Treating Non-Critical Novel Coronavirus Pneumonia (COVID-19) (http://www.chictr.org.cn/showprojen.aspx?proj=51028 ) ChiCTR2000030896

CHINAZhengzhou People's Hospital



Fu-Zheng Qing-Fei Thought N/A Improvement of symptoms. 18-75 y.o.

296. Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19 (https://clinicaltrials.gov/ct2/show/NCT04306497?term=NCT04306497 ) NCT04306497

CHINA, Huai'an fourth people's Hospital

Prospective Observational StudyControlled


TCM + Standard Treatment + Antiviral DrugsvsStandard Treatment + Antiviral Drugs

N/A The relief / disappearance rate of main symptoms [Time Frame: 9days]Disappearance of fever, cough and shortness of breath/ the rate of complete relief.Chest CT absorption [Time Frame: 9days]With reference to the "pneumonia chest X-ray absorption Evaluation scale" developed by Renyi Yin et al, the final absorption judgment will be used to evaluate the chest CT absorption of patients with pneumonia, which is divided into four levels according to the degree of absorption: complete absorption, majority absorption, partial absorption and no absorption.

18-75 y.o.

297. ExocarpiumCitri Grandis Relieves Symptoms of Novel Coronavirus Pneunomia (COVID-19): a

CHINA, Maoming People's Hospital, Guangdong

InterventionalRandomised Placebo-controlled


Oral Administration of ExocarpiumCitri Grandis Phlegm Cough Solution

N/A Cough Score, Expectoration score.

18-75y.o.















Randomized Controlled Clinical Trial (http://www.chictr.org.cn/showprojen.aspx?proj=51018 ) ChiCTR2000030804

vsOral Placebo

298. A medical records based real world study for the characteristics and correlation mechanism of traditional Chinese medicine combined with western medicine in the treatment of patients with novel coronavirus pneumonia (COVID-19) (http://www.chictr.org.cn/showprojen.aspx?proj=50656 ) ChiCTR2000030619

CHINA,The First Affiliated Hospital of Bengbu Medical College



Traditional Chinese Medicine +Western Medicine

N/A Treatment effect. N/A

299. Clinical efficacy of TCM syndrome differentiation in the treatment of severe/critical type of novel coronavirus pneumonia (COVID-19): a prospective, observational, one-arm clinical study (http://www.chictr.org.cn/showprojen.aspx?proj=51254 ) ChiCTR2000030962

CHINA, Wuhan Union Hospital Wuhan Red Cross Hospital

ProspectiveObservationalStudy Multicentre


Standard treatment + Syndrome differentiation and treatment of TCM

N/A Fatality rate, The ratio of patients transforming from severe/critical to light, Non-invasive/invasive mechanical ventilation time.

≥18y.o.

300. YinhuQingwenGranula for the Treatment of Severe CoVID-19 (https://clinicaltrials.gov/ct2/show/NCT04310865?term=NCT04310865 ) NCT04310865

CHINA, Wuhan No.7 Hospital/Jizhong Energy Fengfeng Group Hospital Wuhan No.7 Hospital/North China University Zhongnan Hospital of Wuhan University/Tanshan People's Hospital Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University Wuhan

Interventional RandomisedDouble-blindParallel-controlled


YinhuQingwenGranula + Standard TreatmentvsLow Dose YinhuQingwenGranula + Standard Treatment

Experimental Group: Granula dissolved into 600ml decoction and divided into 3. 200ml TID (PO) for 10 days Control Group: 10% of granula

Changes in the ratio of PaO2 to FiO2 from baseline [Time Frame: Day 10].

≥18y.o.

301. Study for the effect of Moxibustion Guidance and Intervention based on internet for the discharged patients with novel coronavirus pneumonia (http://www.chictr.org.cn/showprojen.aspx?proj=51030 ) ChiCTR2000031203

CHINA, Zhengzhou People's Hospital

InterventionalParallel-controlled


Moxibustion treatmentvsBlank

N/A TCM Syndrome Scale, Self-Rating Anxiety Scale.

18-75y.o.












302. A RCT for Hua-Shi Bai-Du granules in patients with novel coronavirus pneumonia (COVID-19) (http://www.chictr.org.cn/showprojen.aspx?proj=51317 ) ChiCTR2000030988

CHINA, Hospital of Leishenshan

Interventional Randomised ControlledOpen-label


Chinese Herb Medicine Huashibaidu granulesvsStandard treatment of western medicine

N/A Inflammation absorption on Chest CT.

18-85y.o.

303. Clinical Research for Traditional Mongolian Medicine in the treatment of novel coronavirus pneumonia (COVID-19) (http://www.chictr.org.cn/showprojen.aspx?proj=50941 ) ChiCTR2000030751

CHINA,Affiliated Hospital of Inner Mongolia University for the Nationalities, Tongliao


Traditional Mongolian Medicine

Traditional Mongolian Medicine

N/A Nucleic acids probing, Blood routine tests, Blood biochemistry, Urine Routine, Blood Gas Analysis, Computed Tomography.

18-70y.o.

304. Retrospective study for the efficacy of ulinastatin combined with ''clear lung detoxification soup'' in the treatment of novel coronavirus pneumonia (COVID-19) (http://www.chictr.org.cn/showprojen.aspx?proj=51029 ) ChiCTR2000030806

CHINA,Wuhan Third Hospital


Trypsin-Inhibitor(Ulinastatin)Traditional Chinese Medicine

Oral Chinese medicine "qingfei detoxification soup" + intravenous injection of ulinastatin

Ulinastatin: 200000 U BID (IV)

Blood routine tests, Arterial blood gases, Blood clotting function, Liver and kidney function.

18-75y.o.

305. A clinical trial for Ulinastatin Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19) (http://www.chictr.org.cn/showprojen.aspx?proj=50973 ) ChiCTR2000030779

CHINAshanghai changzhen hospital Guanggu District, Hubei maternal and Child Health Hospital


Trypsin-Inhibitor(Ulinastatin)

Conventional treatment and UlinastatinvsStandard treatment

N/A Blood gas, SOFA score. 18-75y.o.

306. Study for the effect of early endotracheal intubation on the outcome of novel coronavirus pneumonia (COVID-19) patients ChiCTR2000030056



Ventilation/Oxygenation Strategies(Early endotracheal intubation)

Patients who received early endotracheal intubation

N/A ICU hospitalisation days, Death rate, Hospitalisation days.

N/A

307. Study for timing of mechanical ventilation for critically ill patients with novel coronavirus pneumonia (COVID-19): A medical records based retrospective Cohort study (http://www.chictr.org.cn/showprojen.aspx?proj=50459 ) ChiCTR2000030485

CHINA,Tongji Hospital, Huazhong University of Science and Technology, Wuhan Jinyintan Hospital, Wuhan Pulmonary Hospital


Ventilation/Oxygenation Strategies

Aggressive mechanical ventilationvsConservative mechanical ventilation

N/A 28-days mortality, ICU 14-day mortality.

14-90y.o.

308. A Medical Records Based Study for the Effectiveness of Extracorporeal Membrane Oxygenation in Patients with Severe Novel Coronavirus Pneumonia (COVID-19)

CHINA,Zhongnan hospital of Wuhan University


Ventilation/Oxygenation Strategies(Extracorporeal Membrane Oxygenation -ECMO)

Patients who received ECMO N/A Inhospital length, Inhospital mortality, Extracorporeal membrane oxygenation (ECMO) treatment length, 28th day mortality after admission.

≥18y.o.

















ChiCTR2000029949309. A medical records based study for

clinical application of extracorporeal membrane oxygenation in the treatment of severe respiratory failure patients with novel coronavirus pneumonia (COVID-19) (http://www.chictr.org.cn/showprojen.aspx?proj=51267 ) ChiCTR2000030947

CHINA, Wuhan jinyintan hospital

Retrospective, Observational Study


Patients who received ECMO N/A Hospital mortality. 38-70y.o.

310. Clinical Application of ECMO(or Ultra-Protective Lung Mechanical Ventilation) in the Treatment of Patients with ARDS due to novel Coronavirus Pneumonia (COVID-19) (http://www.chictr.org.cn/showprojen.aspx?proj=50910 ) ChiCTR2000030744

CHINA,Shandong Provincial Chest hospital, Qilu Hospital of Shandong University Binzhou Medical University Hospital , The Affiliated Hospital of Qingdao University

Interventional Non-randomised Parallel-controlled


ECMOvsStandard treatment

N/A Inpatient mortality, ICU hospital stay.

14-40y.o.

311. Observational Study for Prone Position Ventilation and Conventional Respiratory Support in ARDS Patients with Novel Coronavirus Pneumonia (COVID-19) (http://www.chictr.org.cn/showprojen.aspx?proj=50907 ) ChiCTR2000030741

CHINA,Shandong Provincial Chest hospital, Qilu Hospital of Shandong University Binzhou Medical University Hospital, The Affiliated Hospital of Qingdao University

SequentialObservational StudyMulticentre

Ventilation/Oxygenation Strategies

Transnasal high-flow oxygen therapyvsNon-invasive mechanical ventilationvsInvasive mechanical ventilation

N/A Arterial partial pressure of oxygen (PaO2), Arterial partial pressure of oxygen carbon dioxide (PaCO2).

14-90y.o.

312. Sequential Oxygen Therapy Strategy for Patients With COVID-19 (https://clinicaltrials.gov/ct2/show/NCT04312100 ) NCT04312100

CHINA, Henan Provincial People's Hospital


Ventilation/Oxygenation Strategies(Non-invasive oxygen therapy)

Mild cases with conventional oxygen therapy vsModerate/Severe cases with nasal high flow oxygen inhalation vsModerate/Severe cases with non-invasive ventilation

N/A Incidence of respiratory failure [Time Frame: 28 day]Incidence of respiratory failure at day 28 after enrolment

18-75y.o.

Trials retrieved from: the European Union Clinical Trials Register (https://www.clinicaltrialsregister.eu/ctr-search/search?query=covid-19), the U.S. National Library of Medicine, ClinicalTrials.gov (https://clinicaltrials.gov/) and the Chinese Clinical Trial Registry (ChiCTR) (http://www.chictr.org.cn/enindex.aspx) up to 26th March 2020.

*Trial is testing both treatment and prevention strategies.

BID: twice daily, CPAP: continuous positive airway pressure, d: day(s), g: grammars, GM-CSF: Granulocyte-macrophage colony-stimulating factor, h: hour, IL: Interleukin, INH: Inhalation, IV: intravenous, kg: kilograms, mg: milligrams, min: minutes, ml: millilitres, N/A: not available, NEB: Nebulisation, OD: once daily, PO: orally, SC: subcutaneous, TCM: Traditional Chinese Medicine, TID: thrice daily, y.o: years old, U: Units

http://www.chictr.org.cn/enindex.aspx

https://clinicaltrials.gov/

https://www.clinicaltrialsregister.eu/ctr-search/search?query=covid-19









Documents

ars.els-cdn.com · Web viewTable S1: Clinical trials currently being undertaken globally for the treatment of novel coronavirus (COVID-19) pneumonia. REGISTRATION NUMBER & TITLE